CSK
Normalized values from positional scanning peptide array
Phospho-serine (pS) is a duplicate of phospho-tyrosine (pT) in PSPA
Position-wise Probabilities
Log-Odds: Probabilities / STY Background
Sites with acceptor types representing >8% and count ≥10 are included
S Sites Probabilities
Y Sites Probabilities
Log-Odds: S Sites / S Background
Log-Odds: Y Sites / Y Background
Sites with acceptor types representing >8% and count ≥10 are included
Motif clusters with count ≥ 10 are shown
Download
| substrate_uniprot | site | source | substrate_genes | site_seq |
|---|---|---|---|---|
| A5A3E0 | S939 | Sugiyama | POTEF A26C1B | VALDFEQEMATVAsSSSLEKsyELPDGQVItIGNERFRCPE |
| A5A3E0 | Y1062 | Sugiyama | POTEF A26C1B | GGSILASLSTFQQMWISKQEyDEsGPsIVHRKCL_______ |
| A5A3E0 | Y940 | Sugiyama | POTEF A26C1B | ALDFEQEMATVAsSSSLEKsyELPDGQVItIGNERFRCPEA |
| O00116 | Y645 | Sugiyama | AGPS AAG5 | QWLKESIsDVGFGMLKSVKEyVDPNNIFGNRNLL_______ |
| O00299 | Y233 | Sugiyama | CLIC1 G6 NCC27 | AyAREEFAstCPDDEEIELAyEQVAKALK____________ |
| O00469 | Y444 | Sugiyama | PLOD2 | LWSNFWGALSPDGYYARsEDyVDIVQGNRVGVWNVPYMANV |
| O14818 | Y176 | Sugiyama | PSMA7 HSPC | WKANAIGRGAKSVREFLEKNyTDEAIETDDLTIKLVIKALL |
| O14950 | Y156 | Sugiyama | MYL12B MRLC2 MYLC2B | DEEVDELyREAPIDKKGNFNyIEFtRILKHGAKDKDD____ |
| O15371 | Y50 | Sugiyama | EIF3D EIF3S7 | yQPFsKGDRLGKVADWtGAtyQDKRYTNKYSSQFGGGSQYA |
| O15492 | Y168 | iPTMNet | RGS16 RGSR | TATCFDAAQGKTRTLMEKDSyPRFLKSPAyRDLAAQASAAS |
| O43390 | Y136 | Sugiyama | HNRNPR HNRPR | QESTKGPDEAKIKALLERtGytLDVttGQRKYGGPPPDSVY |
| O43707 | Y212 | Sugiyama | ACTN4 | WKDGLAFNALIHRHRPELIEyDKLRKDDPVTNLNNAFEVAE |
| O43707 | Y441 | Sugiyama | ACTN4 | KAsIHEAWtDGKEAMLKHRDyEtAtLsDIKALIRKHEAFEs |
| O43852 | Y106 | Sugiyama | CALU | GFVtVDELKDWIKFAQKRWIyEDVERQWKGHDLNEDGLVsW |
| O43852 | Y263 | Sugiyama | CALU | KNRDGKMDKEEtKDWILPsDyDHAEAEARHLVyEsDQNKDG |
| O43852 | Y47 | Sugiyama | CALU | RVHHEPQLsDKVHNDAQsFDyDHDAFLGAEEAKtFDQLtPE |
| O60331 | Y649 | GPS6|EPSD | PIP5K1C KIAA0589 | DEEDAPATDIyFPTDERSWVysPLHYSAQAPPAsDGEsDT_ |
| O60361 | Y136 | Sugiyama | NME2P1 | SLRFKPEELVDYKSCAHDWVyE___________________ |
| O60506 | Y133 | Sugiyama | SYNCRIP HNRPQ NSAP1 | ADSSKGPDEAKIKALLERtGytLDVttGQRKYGGPPPDSVY |
| O60664 | Y95 | Sugiyama | PLIN3 M6PRBP1 TIP47 | VsGAQPILSKLEPQIAsAsEyAHRGLDKLEENLPILQQPTE |
| O60739 | Y30 | Sugiyama | EIF1B | FDPFADATKGDDLLPAGTEDyIHIRIQQRNGRKtLttVQGI |
| O75116 | Y936 | Sugiyama | ROCK2 KIAA0619 | EITLTKADSEQLARsIAEEQysDLEKEKIMKELEIKEMMAR |
| O75223 | Y156 | Sugiyama | GGCT C7orf24 CRF21 | sPQYKKIICMGAKENGLPLEyQEKLKAIEPNDytGKVsEEI |
| O75347 | Y75 | Sugiyama | TBCA | EILQEsRMMIPDCQRRLEAAyLDLQRILENEKDLEEAEEyK |
| O75347 | Y94 | Sugiyama | TBCA | AyLDLQRILENEKDLEEAEEyKEARLVLDsVKLEA______ |
| O95218 | Y167 | Sugiyama | ZRANB2 ZIS ZNF265 | EVEDKEsEGEEEDEDEDLsKyKLDEDEDEDDADLsKyNLDA |
| O95297 | Y263 | Sugiyama | MPZL1 PZR UNQ849/PRO1787 | QLDHsGGHHSDKINKSEsVVyADIRKN______________ |
| O95757 | Y30 | Sugiyama | HSPA4L APG1 HSPH3 OSP94 | FLNCYIAVARsGGIETIANEySDRCtPACIsLGSRTRAIGN |
| P00338 | Y10 | Sugiyama | LDHA PIG19 | ___________MAtLKDQLIyNLLKEEQtPQNKITVVGVGA |
| P00338 | Y239 | Sugiyama | LDHA PIG19 | GtDKDKEQWKEVHKQVVEsAyEVIKLKGYtSWAIGLSVADL |
| P00390 | Y371 | Sugiyama | GSR GLUR GRD1 | TDDKGHIIVDEFQNtNVKGIyAVGDVCGKALLtPVAIAAGR |
| P00558 | Y161 | Sugiyama | PGK1 PGKA MIG10 OK/SW-cl.110 | KAEPAKIEAFRAsLSKLGDVyVNDAFGtAHRAHssMVGVNL |
| P00558 | Y196 | Sugiyama | PGK1 PGKA MIG10 OK/SW-cl.110 | MVGVNLPQKAGGFLMKKELNyFAKALEsPERPFLAILGGAK |
| P00966 | Y163 | Sugiyama | ASS1 ASS | APWRMPEFYNRFKGRNDLMEyAKQHGIPIPVtPKNPWSMDE |
| P02786 | Y152 | Sugiyama | TFRC | sEKLDstDFTGtIKLLNENsyVPREAGsQKDENLALyVENQ |
| P04080 | Y97 | Sugiyama | CSTB CST6 STFB | NKPLtLsNyQTNKAKHDELtyF___________________ |
| P04406 | Y314 | Sugiyama | GAPDH GAPD CDABP0047 OK/SW-cl.12 | tFDAGAGIALNDHFVKLIsWyDNEFGysNRVVDLMAHMAsK |
| P04632 | Y87 | Sugiyama | CAPNS1 CAPN4 CAPNS | sAISEAAAQYNPEPPPPRtHysNIEANEsEEVRQFRRLFAQ |
| P05362 | Y455 | Sugiyama | ICAM1 | GtFPLPIGEsVtVtRDLEGtyLCRARSTQGEVTRKVTVNVL |
| P05386 | S101 | Sugiyama | RPLP1 RRP1 | APstAAAPAEEKKVEAKKEEsEEsDDDMGFGLFD_______ |
| P05386 | S104 | Sugiyama | RPLP1 RRP1 | tAAAPAEEKKVEAKKEEsEEsDDDMGFGLFD__________ |
| P05387 | S102 | Sugiyama | RPLP2 D11S2243E RPP2 | PAAGsAPAAAEEKKDEKKEEsEEsDDDMGFGLFD_______ |
| P05387 | S105 | Sugiyama | RPLP2 D11S2243E RPP2 | GsAPAAAEEKKDEKKEEsEEsDDDMGFGLFD__________ |
| P05787 | Y204 | Sugiyama | KRT8 CYK8 | NKRTEMENEFVLIKKDVDEAyMNKVELESRLEGLTDEINFL |
| P06239 | Y505 | GPS6|SIGNOR|iPTMNet|EPSD|PSP | LCK | PTFDyLRSVLEDFFtAtEGQyQPQP________________ |
| P06241 | Y531 | GPS6|ELM|iPTMNet|EPSD|PSP | FYN | PTFEYLQSFLEDYFtAtEPQyQPGENL______________ |
| P06733 | S268 | Sugiyama | ENO1 ENO1L1 MBPB1 MPB1 | ASEFFRsGKyDLDFKsPDDPsRyIsPDQLADLyKsFIKDyP |
| P06733 | Y257 | Sugiyama | ENO1 ENO1L1 MBPB1 MPB1 | TDKVVIGMDVAASEFFRsGKyDLDFKsPDDPsRyIsPDQLA |
| P06733 | Y270 | Sugiyama | ENO1 ENO1L1 MBPB1 MPB1 | EFFRsGKyDLDFKsPDDPsRyIsPDQLADLyKsFIKDyPVV |
| P06733 | Y280 | Sugiyama | ENO1 ENO1L1 MBPB1 MPB1 | DFKsPDDPsRyIsPDQLADLyKsFIKDyPVVsIEDPFDQDD |
| P06733 | Y407 | Sugiyama | ENO1 ENO1L1 MBPB1 MPB1 | GLCtGQIKTGAPCRSERLAKyNQLLRIEEELGsKAKFAGRN |
| P06733 | Y44 | Sugiyama | ENO1 ENO1L1 MBPB1 MPB1 | LFtsKGLFRAAVPsGAstGIyEALELRDNDKtRYMGKGVSK |
| P07205 | Y161 | Sugiyama | PGK2 PGKB | KAEPDKIEAFRAsLSKLGDVyVNDAFGtAHRAHSSMVGVNL |
| P07237 | Y94 | Sugiyama | P4HB ERBA2L PDI PDIA1 PO4DB | GSEIRLAKVDAtEEsDLAQQyGVRGyPtIKFFRNGDTASPK |
| P07355 | Y188 | Sugiyama | ANXA2 ANX2 ANX2L4 CAL1H LPC2D | RKLMVALAKGRRAEDGsVIDyELIDQDARDLyDAGVKRKGT |
| P07437 | Y50 | Sugiyama | TUBB TUBB5 OK/SW-cl.56 | IDPTGtyHGDsDLQLDRIsVyyNEAtGGKyVPRAILVDLEP |
| P07437 | Y51 | Sugiyama | TUBB TUBB5 OK/SW-cl.56 | DPTGtyHGDsDLQLDRIsVyyNEAtGGKyVPRAILVDLEPG |
| P07686 | Y547 | Sugiyama | HEXB HCC7 | DRLTRHRCRMVERGIAAQPLyAGyCNHENM___________ |
| P07814 | Y1504 | Sugiyama | EPRS1 EPRS GLNS PARS QARS QPRS PIG32 | KPLCELQPGAKCVCGKNPAKyytLFGRsy____________ |
| P07814 | Y1505 | Sugiyama | EPRS1 EPRS GLNS PARS QARS QPRS PIG32 | PLCELQPGAKCVCGKNPAKyytLFGRsy_____________ |
| P07900 | Y197 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | GEPMGRGTKVILHLKEDQtEyLEERRIKEIVKKHSQFIGyP |
| P07900 | Y284 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | DEEEEKKDGDKKKKKKIKEKyIDQEELNKtKPIWtRNPDDI |
| P07900 | Y309 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | ELNKtKPIWtRNPDDItNEEyGEFyKsLtNDWEDHLAVKHF |
| P07900 | Y313 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | tKPIWtRNPDDItNEEyGEFyKsLtNDWEDHLAVKHFSVEG |
| P07900 | Y492 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | DEMVsLKDYCTRMKENQKHIyyItGETKDQVANsAFVERLR |
| P07900 | Y493 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | EMVsLKDYCTRMKENQKHIyyItGETKDQVANsAFVERLRK |
| P07900 | Y61 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | KEIFLRELIsNssDALDKIRyEsLtDPsKLDsGKELHINLI |
| P07947 | Y537 | GPS6|EPSD|PSP | YES1 YES | PTFEYIQSFLEDYFTATEPQyQPGENL______________ |
| P07948 | Y508 | GPS6|SIGNOR|ELM|iPTMNet|EPSD | LYN JTK8 | PTFDYLQsVLDDFytAtEGQyQQQP________________ |
| P08238 | Y192 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | GEPIGRGTKVILHLKEDQtEyLEERRVKEVVKKHsQFIGyP |
| P08238 | Y276 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | DEEDDsGKDKKKKTKKIKEKyIDQEELNKtKPIWtRNPDDI |
| P08238 | Y301 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | ELNKtKPIWtRNPDDItQEEyGEFyKsLtNDWEDHLAVKHF |
| P08238 | Y305 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | tKPIWtRNPDDItQEEyGEFyKsLtNDWEDHLAVKHFSVEG |
| P08238 | Y472 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | sELLRyHtsQsGDEMtsLsEyVsRMKEtQKsIyyItGEsKE |
| P08238 | Y484 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | DEMtsLsEyVsRMKEtQKsIyyItGEsKEQVANsAFVERVR |
| P08238 | Y485 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | EMtsLsEyVsRMKEtQKsIyyItGEsKEQVANsAFVERVRK |
| P08238 | Y56 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | KEIFLRELIsNAsDALDKIRyEsLtDPsKLDsGKELKIDII |
| P08575 | Y1218 | SIGNOR | PTPRC CD45 | FQVVKALRKARPGMVSTFEQyQFLYDVIASTYPAQNGQVKK |
| P08631 | Y411 | EPSD|PSP | HCK | ASLVCKIADFGLARVIEDNEytAREGAKFPIKWTAPEAINF |
| P08631 | Y522 | iPTMNet | HCK | PTFEYIQSVLDDFYTAtEsQyQQQP________________ |
| P09104 | Y44 | Sugiyama | ENO2 | LyTAKGLFRAAVPsGAstGIyEALELRDGDKQRYLGKGVLK |
| P09651 | Y341 | Sugiyama | HNRNPA1 HNRPA1 | QSSNFGPMKGGNFGGRssGPyGGGGQyFAKPRNQGGyGGss |
| P09651 | Y347 | Sugiyama | HNRNPA1 HNRPA1 | PMKGGNFGGRssGPyGGGGQyFAKPRNQGGyGGssssssyG |
| P09769 | Y523 | GPS6|SIGNOR|ELM|iPTMNet|EPSD | FGR SRC2 | PTFEYLQSFLEDYFTSAEPQyQPGDQT______________ |
| P0CG38 | Y1062 | Sugiyama | POTEI | GGSILASLSTFQQMWISKQEyDEsGPsIVHRKCF_______ |
| P0CG39 | Y1025 | Sugiyama | POTEJ | GGSILASLSTFQQMWISKQEyDEsGPsIVHRKCF_______ |
| P10636 | Y29 | PSP | MAPT MAPTL MTBT1 TAU | EVMEDHAGTyGLGDRKDQGGytMHQDQEGDtDAGLKEsPLQ |
| P11047 | Y352 | Sugiyama | LAMC1 LAMB2 | tAEsASECLPCDCNGRsQECyFDPELyRSTGHGGHCTNCQD |
| P11142 | S40 | Sugiyama | HSPA8 HSC70 HSP73 HSPA10 | VFQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVA |
| P11940 | Y194 | Sugiyama | PABPC1 PAB1 PABP PABP1 PABPC2 | KSRKEREAELGARAKEFtNVyIKNFGEDMDDERLKDLFGKF |
| P11940 | Y291 | Sugiyama | PABPC1 PAB1 PABP PABP1 PABPC2 | ERQTELKRKFEQMKQDRITRyQGVNLyVKNLDDGIDDERLR |
| P11940 | Y297 | Sugiyama | PABPC1 PAB1 PABP PABP1 PABPC2 | KRKFEQMKQDRITRyQGVNLyVKNLDDGIDDERLRKEFsPF |
| P12004 | Y249 | Sugiyama | PCNA | MSADVPLVVEYKIADMGHLKyyLAPKIEDEEGs________ |
| P12004 | Y250 | Sugiyama | PCNA | SADVPLVVEYKIADMGHLKyyLAPKIEDEEGs_________ |
| P12277 | Y125 | Sugiyama | CKB CKBB | EHKTDLNPDNLQGGDDLDPNyVLssRVRTGRSIRGFCLPPH |
| P12277 | Y39 | Sugiyama | CKB CKBB | EFPDLSAHNNHMAKVLtPELyAELRAKSTPSGFTLDDVIQT |
| P12814 | Y842 | Sugiyama | ACTN1 | DTDTADQVMASFKILAGDKNyITMDELRRELPPDQAEyCIA |
| P12931 | Y419 | EPSD|PSP | SRC SRC1 | ENLVCKVADFGLARLIEDNEytARQGAKFPIKWTAPEAALy |
| P12931 | Y530 | GPS6|SIGNOR|ELM|iPTMNet|EPSD|PSP | SRC SRC1 | PTFEYLQAFLEDyFtstEPQyQPGENL______________ |
| P13639 | Y671 | Sugiyama | EEF2 EF2 | CFGPDGTGPNILTDITKGVQyLNEIKDSVVAGFQWATKEGA |
| P13667 | Y565 | Sugiyama | PDIA4 ERP70 ERP72 | DVLIEFYAPWCGHCKQLEPVyNsLAKKYKGQKGLVIAKMDA |
| P13674 | Y282 | Sugiyama | P4HA1 P4HA | ASDDQSDQKTTPKKKGVAVDyLPERQKyEMLCRGEGIKMTP |
| P13929 | Y44 | Sugiyama | ENO3 | LHtAKGRFRAAVPsGAstGIyEALELRDGDKGRYLGKGVLK |
| P14314 | Y106 | Sugiyama | PRKCSH G19P1 | yIPSNRVNDGVCDCCDGtDEyNsGVICENtCKEKGRKEREs |
| P14625 | Y258 | Sugiyama | HSP90B1 GRP94 HSPC4 TRA1 | GNTLGRGTTITLVLKEEAsDyLELDTIKNLVKKYSQFINFP |
| P14625 | Y429 | Sugiyama | HSP90B1 GRP94 HSPC4 TRA1 | IKLYVRRVFITDDFHDMMPKyLNFVKGVVDsDDLPLNVsRE |
| P14625 | Y539 | Sugiyama | HSP90B1 GRP94 HSPC4 TRA1 | tDItsLDQyVERMKEKQDKIyFMAGsSRKEAEssPFVERLL |
| P14649 | S87 | Sugiyama | MYL6B MLC1SA | EEFKEAFELFDRVGDGKILysQCGDVMRALGQNPtNAEVLK |
| P14649 | Y86 | Sugiyama | MYL6B MLC1SA | LEEFKEAFELFDRVGDGKILysQCGDVMRALGQNPtNAEVL |
| P15259 | Y92 | Sugiyama | PGAM2 PGAMM | DGTDQMWLPVVRTWRLNERHyGGLtGLNKAETAAKHGEEQV |
| P15880 | S249 | Sugiyama | RPS2 RPS4 | CtAtLGNFAKATFDAISKTysyLtPDLWKEtVFtKsPyQEF |
| P15880 | Y250 | Sugiyama | RPS2 RPS4 | tAtLGNFAKATFDAISKTysyLtPDLWKEtVFtKsPyQEFt |
| P15941 | Y1229 | GPS6|EPSD | MUC1 PUM | yPtyHtHGRyVPPsstDRsPyEKVsAGNGGssLsytNPAVA |
| P16284 | Y713 | SIGNOR | PECAM1 | VQVSsAEsHKDLGKKDtEtVysEVRKAVPDAVEsRYsRtEG |
| P17066 | S42 | Sugiyama | HSPA6 HSP70B' | VFQQGRVEILANDQGNRTtPsyVAFtDtERLVGDAAKsQAA |
| P17987 | S544 | Sugiyama | TCP1 CCT1 CCTA | ILRIDDLIKLHPESKDDKHGsyEDAVHsGALND________ |
| P17987 | Y545 | Sugiyama | TCP1 CCT1 CCTA | LRIDDLIKLHPESKDDKHGsyEDAVHsGALND_________ |
| P18206 | Y822 | Sugiyama | VCL | KAVAGNIsDPGLQKsFLDsGyRILGAVAKVREAFQPQEPDF |
| P18615 | Y133 | Sugiyama | NELFE RD RDBP | sIsADDDLQEsSRRPQRKsLyEsFVsssDRLRELGPDGEEA |
| P18621 | S5 | Sugiyama | RPL17 | ________________MVRysLDPENPtKsCKSRGSNLRVH |
| P18621 | Y4 | Sugiyama | RPL17 | _________________MVRysLDPENPtKsCKSRGSNLRV |
| P18669 | S137 | Sugiyama | PGAM1 PGAMA CDABP0006 | RsyDVPPPPMEPDHPFysNIsKDRRyADLtEDQLPsCEsLK |
| P18669 | Y119 | Sugiyama | PGAM1 PGAMA CDABP0006 | NKAETAAKHGEAQVKIWRRsyDVPPPPMEPDHPFysNIsKD |
| P18669 | Y142 | Sugiyama | PGAM1 PGAMA CDABP0006 | PPPPMEPDHPFysNIsKDRRyADLtEDQLPsCEsLKDtIAR |
| P18669 | Y92 | Sugiyama | PGAM1 PGAMA CDABP0006 | DAIDQMWLPVVRTWRLNERHyGGLtGLNKAETAAKHGEAQV |
| P19105 | Y155 | Sugiyama | MYL12A MLCB MRLC3 RLC | DEEVDELyREAPIDKKGNFNyIEFtRILKHGAKDKDD____ |
| P19338 | T464 | Sugiyama | NCL | KTFEEKQGtEIDGRsIsLyytGEKGQNQDYRGGKNSTWsGE |
| P19338 | Y462 | Sugiyama | NCL | AEKTFEEKQGtEIDGRsIsLyytGEKGQNQDYRGGKNSTWs |
| P20618 | Y150 | Sugiyama | PSMB1 PSC5 | FPYYVYNIIGGLDEEGKGAVysFDPVGsyQRDsFKAGGSAS |
| P20618 | Y158 | Sugiyama | PSMB1 PSC5 | IGGLDEEGKGAVysFDPVGsyQRDsFKAGGSASAMLQPLLD |
| P21980 | Y369 | Sugiyama | TGM2 | PGYEGWQALDPTPQEKsEGtyCCGPVPVRAIKEGDLstKyD |
| P22234 | Y22 | Sugiyama | PAICS ADE2 AIRC PAIS | AtAEVLNIGKKLYEGKtKEVyELLDsPGKVLLQsKDQItAG |
| P22314 | Y55 | Sugiyama | UBA1 A1S9T UBE1 | SVPTNGMAKNGsEADIDEGLysRQLyVLGHEAMKRLQTSSV |
| P22392 | Y151 | Sugiyama | NME2 NM23B | SLWFKPEELVDyKSCAHDWVyE___________________ |
| P23246 | S491 | Sugiyama | SFPQ PSF | QKEREtPPRFAQHGtFEyEysQRWKsLDEMEKQQREQVEKN |
| P23246 | Y488 | Sugiyama | SFPQ PSF | PMYQKEREtPPRFAQHGtFEyEysQRWKsLDEMEKQQREQV |
| P23246 | Y490 | Sugiyama | SFPQ PSF | YQKEREtPPRFAQHGtFEyEysQRWKsLDEMEKQQREQVEK |
| P23284 | Y119 | Sugiyama | PPIB CYPB | DFMIQGGDFtRGDGtGGKsIyGERFPDENFKLKHyGPGWVs |
| P23434 | Y139 | Sugiyama | GCSH | EVTEINEALAENPGLVNKSCyEDGWLIKMtLsNPsELDELM |
| P23528 | Y140 | Sugiyama | CFL1 CFL | SKDAIKKKLtGIKHELQANCyEEVKDRCTLAEKLGGsAVIs |
| P23528 | Y68 | Sugiyama | CFL1 CFL | ILEEGKEILVGDVGQtVDDPyAtFVKMLPDKDCRyALyDAt |
| P24752 | Y214 | Sugiyama | ACAT1 ACAT MAT | GsCAENTAKKLNIARNEQDAyAINsytRSKAAWEAGKFGNE |
| P25398 | Y127 | Sugiyama | RPS12 | sCVVVKDYGKESQAKDVIEEyFKCKK_______________ |
| P25786 | Y6 | Sugiyama | PSMA1 HC2 NU PROS30 PSC2 | _______________MFRNQyDNDVtVWsPQGRIHQIEYAM |
| P26196 | Y469 | Sugiyama | DDX6 HLR2 RCK | IEEQLGTEIKPIPsNIDKSLyVAEyHsEPVEDEKP______ |
| P26196 | Y473 | Sugiyama | DDX6 HLR2 RCK | LGTEIKPIPsNIDKSLyVAEyHsEPVEDEKP__________ |
| P27348 | Y149 | Sugiyama | YWHAQ | LAEVACGDDRKQtIDNsQGAyQEAFDIsKKEMQPTHPIRLG |
| P27348 | Y48 | Sugiyama | YWHAQ | AVtEQGAELsNEERNLLsVAyKNVVGGRRSAWRVIsSIEQK |
| P27695 | Y45 | Sugiyama | APEX1 APE APE1 APEX APX HAP1 REF1 | KSKTAAKKNDKEAAGEGPALyEDPPDQKtsPsGKPAtLKIC |
| P27797 | Y109 | Sugiyama | CALR CRTC | QTLVVQFTVKHEQNIDCGGGyVKLFPNSLDQTDMHGDSEYN |
| P27816 | Y47 | Sugiyama | MAP4 | AtLEAEAFDDVVGETVGKTDyIPLLDVDEKtGNsESKKKPC |
| P29401 | Y481 | Sugiyama | TKT | AANTKGICFIRTsRPENAIIyNNNEDFQVGQAKVVLKSKDD |
| P29692 | Y26 | Sugiyama | EEF1D EF1D | LAHEKIWFDKFKYDDAERRFyEQMNGPVAGAsRQENGAsVI |
| P30043 | Y205 | Sugiyama | BLVRB FLR SCAN | MLRCLttDEyDGHstyPsHQyQ___________________ |
| P30085 | Y49 | Sugiyama | CMPK1 CMK CMPK UCK UMK UMPK | ytHLSAGELLRDERKNPDsQyGELIEKYIKEGKIVPVEITI |
| P30086 | Y64 | Sugiyama | PEBP1 PBP PEBP | tQVKNRPtsIsWDGLDsGKLytLVLtDPDAPsRKDPKYREW |
| P30101 | Y100 | Sugiyama | PDIA3 ERP57 ERP60 GRP58 | LAKVDCTANTNTCNKyGVsGyPtLKIFRDGEEAGAyDGPRt |
| P30101 | Y115 | Sugiyama | PDIA3 ERP57 ERP60 GRP58 | yGVsGyPtLKIFRDGEEAGAyDGPRtADGIVsHLKKQAGPA |
| P30101 | Y67 | Sugiyama | PDIA3 ERP57 ERP60 GRP58 | LMLVEFFAPWCGHCKRLAPEyEAAAtRLKGIVPLAKVDCTA |
| P30101 | Y95 | Sugiyama | PDIA3 ERP57 ERP60 GRP58 | KGIVPLAKVDCTANTNTCNKyGVsGyPtLKIFRDGEEAGAy |
| P31943 | Y266 | Sugiyama | HNRNPH1 HNRPH HNRPH1 | yNGYNDGYGFGSDRFGRDLNyCFsGMsDHRyGDGGstFQst |
| P31946 | Y151 | Sugiyama | YWHAB | LsEVAsGDNKQTtVsNsQQAyQEAFEIsKKEMQPTHPIRLG |
| P31946 | Y50 | Sugiyama | YWHAB | AVtEQGHELsNEERNLLsVAyKNVVGARRSsWRVIsSIEQK |
| P31947 | Y151 | Sugiyama | SFN HME1 | LAEVATGDDKKRIIDSARsAyQEAMDISKKEMPPTNPIRLG |
| P31947 | Y48 | Sugiyama | SFN HME1 | GAVEKGEELsCEERNLLsVAyKNVVGGQRAAWRVLSsIEQK |
| P31948 | Y354 | Sugiyama | STIP1 | DVLKKCQQAEKILKEQERLAyINPDLALEEKNKGNECFQKG |
| P31948 | Y41 | Sugiyama | STIP1 | DDALQCysEAIKLDPHNHVLysNRsAAyAKKGDYQKAyEDG |
| P32969 | Y180 | Sugiyama | RPL9 OK/SW-cl.103; RPL9P7; RPL9P8; RPL9P9 | LIQQATTVKNKDIRKFLDGIyVsEKGtVQQADE________ |
| P34931 | S42 | Sugiyama | HSPA1L | VFQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVA |
| P34932 | Y30 | Sugiyama | HSPA4 APG2 HSPH2 | FQSCYVAVARAGGIETIANEysDRCtPACIsFGPKNRSIGA |
| P35222 | Y654 | GPS6|EPSD | CTNNB1 CTNNB OK/SW-cl.35 PRO2286 | EGATAPLTELLHsRNEGVAtyAAAVLFRMSEDKPQDyKKRL |
| P35222 | Y86 | GPS6|EPSD | CTNNB1 CTNNB OK/SW-cl.35 PRO2286 | WEQGFSQsFTQEQVADIDGQyAMTRAQRVRAAMFPEtLDEG |
| P36871 | Y476 | Sugiyama | PGM1 | GKQFSANDKVYtVEKADNFEysDPVDGsIsRNQGLRLIFTD |
| P37802 | Y192 | Sugiyama | TAGLN2 KIAA0120 CDABP0035 | NVIGLQMGtNRGAsQAGMtGyGMPRQIL_____________ |
| P38646 | Y118 | Sugiyama | HSPA9 GRP75 HSPA9B mt-HSP70 | ERLVGMPAKRQAVtNPNNtFyAtKRLIGRRYDDPEVQKDIK |
| P38646 | Y196 | Sugiyama | HSPA9 GRP75 HSPA9B mt-HSP70 | EtAENyLGHtAKNAVItVPAyFNDsQRQAtKDAGQIsGLNV |
| P39019 | Y48 | Sugiyama | RPS19 | LKVPEWVDtVKLAKHKELAPyDENWFytRAAstARHLYLRG |
| P39019 | Y54 | Sugiyama | RPS19 | VDtVKLAKHKELAPyDENWFytRAAstARHLYLRGGAGVGs |
| P40261 | Y11 | Sugiyama | NNMT | __________MESGFTSKDTyLSHFNPRDYLEKYYKFGSRH |
| P40429 | Y149 | Sugiyama | RPL13A | LKPTRKFAYLGRLAHEVGWKyQAVtAtLEEKRKEKAKIHYR |
| P41240 | Y116 | Sugiyama | CSK | LyPPETGLFLVRESTNYPGDyTLCVSCDGKVEHYRIMYHAS |
| P41240 | Y184 | Sugiyama | CSK | CTRLIKPKVMEGTVAAQDEFyRSGWALNMKELKLLQTIGKG |
| P41240 | Y214 | Sugiyama | CSK | ELKLLQTIGKGEFGDVMLGDyRGNKVAVKCIKNDATAQAFL |
| P41240 | Y263 | Sugiyama | CSK | LRHSNLVQLLGVIVEEKGGLyIVTEyMAKGSLVDYLRSRGR |
| P41240 | Y268 | Sugiyama | CSK | LVQLLGVIVEEKGGLyIVTEyMAKGSLVDYLRSRGRSVLGG |
| P41240 | Y304 | SIGNOR|iPTMNet | CSK | SVLGGDCLLKFSLDVCEAMEyLEGNNFVHRDLAARNVLVSE |
| P41240 | Y416 | Sugiyama | CSK | VPRVEKGYKMDAPDGCPPAVyEVMKNCWHLDAAMRPSFLQL |
| P41240 | Y64 | Sugiyama | CSK | DPNWYKAKNKVGREGIIPANyVQKREGVKAGTKLSLMPWFH |
| P41567 | Y30 | Sugiyama | EIF1 SUI1 | FDPFADAsKGDDLLPAGTEDyIHIRIQQRNGRKtLttVQGI |
| P47712 | Y535 | Sugiyama | PLA2G4A CPLA2 PLA2G4 | sFDDDELDAAVADPDEFERIyEPLDVKSKKIHVVDSGLTFN |
| P47756 | Y59 | Sugiyama | CAPZB | LLSSVDQPLKIARDKVVGKDyLLCDyNRDGDSyRsPWSNKy |
| P48741 | S42 | Sugiyama | HSPA7 HSP70B | VFQQGRVEILANDQGNRTtPsyVAFtDtERLVGDAAKsQAA |
| P49023 | Y40 | iPTMNet | PXN | KRPVFLSEETPySYPTGNHTyQEIAVPPPVPPPPSSEALNG |
| P49023 | Y88 | iPTMNet | PXN | QWQPSSSRFIHQQPQsssPVyGssAKtssVsNPQDsVGsPC |
| P49207 | Y34 | Sugiyama | RPL34 | NtASNKTRLSRTPGNRIVyLytKKVGKAPKSACGVCPGRLR |
| P49327 | Y2034 | Sugiyama | FASN FAS | DYFVVFSSVSCGRGNAGQsNyGFANsAMERICEKRRHEGLP |
| P50897 | Y264 | Sugiyama | PPT1 CLN1 PPT | FGFYRsGQAKEtIPLQEtsLytQDRLGLKEMDNAGQLVFLA |
| P50990 | Y30 | Sugiyama | CCT8 C21orf112 CCTQ KIAA0002 | GFAQMLKEGAKHFsGLEEAVyRNIQACKELAQTTRTAYGPN |
| P50991 | Y269 | Sugiyama | CCT4 CCTD SRB | IQFCLSAPKTDMDNQIVVSDyAQMDRVLREERAYILNLVKQ |
| P51858 | Y66 | Sugiyama | HDGF HMG1L2 | QVFFFGTHETAFLGPKDLFPyEEsKEKFGKPNKRKGFsEGL |
| P51965 | Y77 | Sugiyama | UBE2E1 UBCH6 | ADITLDPPPNCSAGPKGDNIyEWRSTILGPPGSVYEGGVFF |
| P52209 | Y137 | Sugiyama | PGD PGDH | KAKGILFVGsGVsGGEEGARyGPSLMPGGNKEAWPHIKTIF |
| P54577 | Y289 | Sugiyama | YARS1 YARS | FPLKSEFVILRDEKWGGNKTytAyVDLEKDFAAEVVHPGDL |
| P54577 | Y292 | Sugiyama | YARS1 YARS | KSEFVILRDEKWGGNKTytAyVDLEKDFAAEVVHPGDLKNS |
| P54652 | S41 | Sugiyama | HSPA2 | VFQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVA |
| P55060 | Y369 | Sugiyama | CSE1L CAS XPO2 | VPNMEFRAADEEAFEDNsEEyIRRDLEGsDIDTRRRAACDL |
| P55209 | Y106 | Sugiyama | NAP1L1 NRP | VKCAQIEAKFyEEVHDLERKyAVLyQPLFDKRFEIINAIYE |
| P55209 | Y110 | Sugiyama | NAP1L1 NRP | QIEAKFyEEVHDLERKyAVLyQPLFDKRFEIINAIYEPTEE |
| P55795 | Y266 | Sugiyama | HNRNPH2 FTP3 HNRPH2 | YGGYNDGYGFGSDRFGRDLNyCFsGMsDHRyGDGGssFQst |
| P60174 | Y209 | Sugiyama | TPI1 TPI | LRGWLKsNVsDAVAQstRIIyGGsVtGAtCKELASQPDVDG |
| P60228 | Y445 | Sugiyama | EIF3E EIF3S6 INT6 | KLNQNSRSEAPNWAtQDsGFy____________________ |
| P60660 | S30 | Sugiyama | MYL6 | AEFKEAFQLFDRtGDGKILysQCGDVMRALGQNPtNAEVLK |
| P60660 | Y29 | Sugiyama | MYL6 | TAEFKEAFQLFDRtGDGKILysQCGDVMRALGQNPtNAEVL |
| P60660 | Y86 | Sugiyama | MYL6 | DFEHFLPMLQTVAKNKDQGtyEDyVEGLRVFDKEGNGtVMG |
| P60660 | Y89 | Sugiyama | MYL6 | HFLPMLQTVAKNKDQGtyEDyVEGLRVFDKEGNGtVMGAEI |
| P60709 | S239 | Sugiyama | ACTB | VALDFEQEMAtAAssssLEKsyELPDGQVItIGNERFRCPE |
| P60709 | Y198 | Sugiyama | ACTB | LDLAGRDLTDyLMKILtERGysFtttAEREIVRDIKEKLCy |
| P60709 | Y240 | Sugiyama | ACTB | ALDFEQEMAtAAssssLEKsyELPDGQVItIGNERFRCPEA |
| P60709 | Y362 | Sugiyama | ACTB | GGsILAsLstFQQMWISKQEyDEsGPsIVHRKCF_______ |
| P60842 | Y197 | Sugiyama | EIF4A1 DDX2A EIF4A | KMFVLDEADEMLsRGFKDQIyDIFQKLNsNtQVVLLSATMP |
| P61081 | Y172 | Sugiyama | UBE2M UBC12 | VLQNNRRLFEQNVQRSMRGGyIGstyFERCLK_________ |
| P61081 | Y177 | Sugiyama | UBE2M UBC12 | RRLFEQNVQRSMRGGyIGstyFERCLK______________ |
| P61221 | Y594 | Sugiyama | ABCE1 RLI RNASEL1 RNASELI RNS4I OK/SW-cl.40 | RPRINKLNsIKDVEQKKsGNyFFLDD_______________ |
| P61247 | Y256 | Sugiyama | RPS3A FTE1 MFTL | sssGKAtGDEtGAKVERADGyEPPVQEsV____________ |
| P61353 | Y85 | Sugiyama | RPL27 | RSKIKSFVKVyNyNHLMPtRysVDIPLDKtVVNKDVFRDPA |
| P61604 | Y100 | Sugiyama | HSPE1 | KVVLDDKDyFLFRDGDILGKyVD__________________ |
| P61604 | Y76 | Sugiyama | HSPE1 | KGGEIQPVsVKVGDKVLLPEyGGtKVVLDDKDyFLFRDGDI |
| P61604 | Y88 | Sugiyama | HSPE1 | GDKVLLPEyGGtKVVLDDKDyFLFRDGDILGKyVD______ |
| P61978 | Y72 | Sugiyama | HNRNPK HNRPK | KNAGAVIGKGGKNIKALRtDyNAsVsVPDssGPERILsISA |
| P61981 | Y49 | Sugiyama | YWHAG | NVtELNEPLsNEERNLLsVAyKNVVGARRSsWRVIsSIEQK |
| P62081 | Y177 | Sugiyama | RPS7 | HLDKAQQNNVEHKVEtFsGVyKKLTGKDVNFEFPEFQL___ |
| P62191 | Y184 | Sugiyama | PSMC1 | MDDTDPLVTVMKVEKAPQETyADIGGLDNQIQEIKESVELP |
| P62191 | Y439 | Sugiyama | PSMC1 | FKKSKENVLyKKQEGtPEGLyL___________________ |
| P62249 | Y115 | Sugiyama | RPS16 | YYQKYVDEASKKEIKDILIQyDRtLLVADPRRCESKKFGGP |
| P62258 | Y152 | Sugiyama | YWHAE | LAEFAtGNDRKEAAENsLVAyKAAsDIAMtELPPTHPIRLG |
| P62258 | Y49 | Sugiyama | YWHAE | KVAGMDVELTVEERNLLsVAyKNVIGARRASWRIIssIEQK |
| P62269 | S96 | Sugiyama | RPS18 D6S218E | QYKIPDWFLNRQKDVKDGKysQVLANGLDNKLREDLERLKK |
| P62269 | Y95 | Sugiyama | RPS18 D6S218E | RQYKIPDWFLNRQKDVKDGKysQVLANGLDNKLREDLERLK |
| P62273 | Y7 | Sugiyama | RPS29 | ______________MGHQQLyWsHPRKFGQGSRSCRVCSNR |
| P62280 | Y55 | Sugiyama | RPS11 | RYYKNIGLGFKtPKEAIEGtyIDKKCPFTGNVsIRGRILsG |
| P62495 | Y345 | Sugiyama | ETF1 ERF1 RF1 SUP45L1 | NLDIMRYVLHCQGTEEEKILyLTPEQEKDKSHFTDKETGQE |
| P62736 | S241 | Sugiyama | ACTA2 ACTSA ACTVS GIG46 | VALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPE |
| P62736 | Y242 | Sugiyama | ACTA2 ACTSA ACTVS GIG46 | ALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPET |
| P62750 | Y144 | Sugiyama | RPL23A | VNtLIRPDGEKKAYVRLAPDyDALDVANKIGII________ |
| P62826 | Y146 | Sugiyama | RAN ARA24 OK/SW-cl.81 | IKDRKVKAKsIVFHRKKNLQyyDIsAKSNyNFEKPFLWLAR |
| P62906 | Y11 | Sugiyama | RPL10A NEDD6 | __________MSSKVsRDtLyEAVREVLHGNQRKRRKFLET |
| P62917 | Y133 | Sugiyama | RPL8 | VCCLEEKPGDRGKLARAsGNyAtVIsHNPEtKKtRVKLPSG |
| P63104 | Y149 | Sugiyama | YWHAZ | LAEVAAGDDKKGIVDQsQQAyQEAFEIsKKEMQPTHPIRLG |
| P63104 | Y48 | Sugiyama | YWHAZ | sVtEQGAELsNEERNLLsVAyKNVVGARRssWRVVssIEQK |
| P63261 | S239 | Sugiyama | ACTG1 ACTG | VALDFEQEMAtAAssssLEKsyELPDGQVItIGNERFRCPE |
| P63261 | Y198 | Sugiyama | ACTG1 ACTG | LDLAGRDLTDyLMKILtERGysFtttAEREIVRDIKEKLCy |
| P63261 | Y240 | Sugiyama | ACTG1 ACTG | ALDFEQEMAtAAssssLEKsyELPDGQVItIGNERFRCPEA |
| P63261 | Y362 | Sugiyama | ACTG1 ACTG | GGsILAsLstFQQMWISKQEyDEsGPsIVHRKCF_______ |
| P63267 | S240 | Sugiyama | ACTG2 ACTA3 ACTL3 ACTSG | VALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPE |
| P63267 | Y241 | Sugiyama | ACTG2 ACTA3 ACTL3 ACTSG | ALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPET |
| P67809 | S209 | Sugiyama | YBX1 NSEP1 YB1 | RRRRFPPyyMRRPYGRRPQysNPPVQGEVMEGADNQGAGEQ |
| P67809 | Y72 | Sugiyama | YBX1 NSEP1 YB1 | KKVIATKVLGTVKWFNVRNGyGFINRNDtKEDVFVHQtAIK |
| P68032 | S241 | Sugiyama | ACTC1 ACTC | VALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPE |
| P68032 | Y242 | Sugiyama | ACTC1 ACTC | ALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPET |
| P68133 | S241 | Sugiyama | ACTA1 ACTA | VALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPE |
| P68133 | Y242 | Sugiyama | ACTA1 ACTA | ALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPET |
| P68363 | Y432 | Sugiyama | TUBA1B | GMEEGEFSEAREDMAALEKDyEEVGVDsVEGEGEEEGEEy_ |
| Q00610 | Y883 | Sugiyama | CLTC CLH17 CLTCL2 KIAA0034 | EARIHEGCEEPAtHNALAKIyIDsNNNPERFLRENPyyDsR |
| Q00839 | Y257 | Sugiyama | HNRNPU C1orf199 HNRPU SAFA U21.1 | QKGGDKKRGVKRPREDHGRGyFEyIEENKysRAKsPQPPVE |
| Q00839 | Y260 | Sugiyama | HNRNPU C1orf199 HNRPU SAFA U21.1 | GDKKRGVKRPREDHGRGyFEyIEENKysRAKsPQPPVEEED |
| Q01130 | Y44 | Sugiyama | SRSF2 SFRS2 | RtsPDtLRRVFEKYGRVGDVyIPRDRYTKESRGFAFVRFHD |
| Q02878 | Y115 | Sugiyama | RPL6 TXREB1 | PVGGDKNGGTRVVKLRKMPRyyPtEDVPRKLLSHGKKPFSQ |
| Q04837 | Y73 | Sugiyama | SSBP1 SSBP | PVTIFSLATNEMWRsGDsEVyQLGDVsQKTTWHRISVFRPG |
| Q04917 | Y49 | Sugiyama | YWHAH YWHA1 | AVtELNEPLsNEDRNLLsVAyKNVVGARRSsWRVIsSIEQK |
| Q06830 | Y116 | Sugiyama | PRDX1 PAGA PAGB TDPX2 | GLGPMNIPLVSDPKRtIAQDyGVLKADEGIsFRGLFIIDDK |
| Q13263 | Y133 | Sugiyama | TRIM28 KAP1 RNF96 TIF1B | TVVDCPVCKQQCFSKDIVENyFMRDsGsKAATDAQDANQCC |
| Q13263 | Y242 | Sugiyama | TRIM28 KAP1 RNF96 TIF1B | ESCDTLTCRDCQLNAHKDHQyQFLEDAVRNQRKLLAsLVKR |
| Q13310 | Y194 | Sugiyama | PABPC4 APP1 PABP4 | KSRKEREAELGAKAKEFtNVyIKNFGEEVDDEsLKELFsQF |
| Q13442 | S19 | Sugiyama | PDAP1 HASPP28 | __MPKGGRKGGHKGRARQytsPEEIDAQLQAEKQKAREEEE |
| Q13561 | Y6 | Sugiyama | DCTN2 DCTN50 | _______________MADPKyADLPGIARNEPDVYETSDLP |
| Q13765 | Y120 | Sugiyama | NACA HSD48 | KNILFVITKPDVYKSPAsDtyIVFGEAKIEDLsQQAQLAAA |
| Q14152 | Y697 | Sugiyama | EIF3A EIF3S10 KIAA0139 | LEKEKKELQERLKNQEKKIDyFERAKRLEEIPLIKSAYEEQ |
| Q14247 | Y334 | Sugiyama | CTTN EMS1 | KDRMDKNAstFEDVtQVssAyQKTVPVEAVtsKtsNIRANF |
| Q14247 | Y446 | Sugiyama | CTTN EMS1 | sFKAELsyRGPVsGtEPEPVysMEAADyREASSQQGLAYAT |
| Q14257 | Y311 | Sugiyama | RCN2 ERC55 | NPDLFLtsEAtDyGRQLHDDyFyHDEL______________ |
| Q14257 | Y313 | Sugiyama | RCN2 ERC55 | DLFLtsEAtDyGRQLHDDyFyHDEL________________ |
| Q14568 | Y283 | Sugiyama | HSP90AA2P HSP90AA2 HSPC2 HSPCAL3 | sDEEEEKKDGDKKKKKTKEKyIDQEELNKTKPIWTRNPDDI |
| Q15056 | Y101 | Sugiyama | EIF4H KIAA0038 WBSCR1 WSCR1 | FKGFCyVEFDEVDsLKEALtyDGALLGDRsLRVDIAEGRKQ |
| Q15181 | Y169 | Sugiyama | PPA1 IOPPP PP | EGETDWKVIAINVDDPDAANyNDINDVKRLKPGYLEATVDW |
| Q15293 | Y278 | Sugiyama | RCN1 RCN | LNKDGKLDKDEIRHWILPQDyDHAQAEARHLVyESDKNKDE |
| Q15427 | Y16 | Sugiyama | SF3B4 SAP49 | _____MAAGPISERNQDAtVyVGGLDEKVSEPLLWELFLQA |
| Q15527 | Y123 | Sugiyama | SURF2 | GRRYQRALCKYEECQKQGVEyVPACLVHRRRRREDQMDGDG |
| Q15785 | Y25 | Sugiyama | TOMM34 URCC3 | FPDsVEELRAAGNESFRNGQyAEASALyGRALRVLQAQGss |
| Q15819 | Y143 | Sugiyama | UBE2V2 MMS2 UEV2 | RRLMMSKENMKLPQPPEGQtyNN__________________ |
| Q16719 | Y441 | Sugiyama | KYNU | RGVVCDKRNPNGIRVAPVPLyNsFHDVyKFTNLLtsILDsA |
| Q16719 | Y448 | Sugiyama | KYNU | RNPNGIRVAPVPLyNsFHDVyKFTNLLtsILDsAETKN___ |
| Q16719 | Y86 | Sugiyama | KYNU | ENAIYFLGNSLGLQPKMVKtyLEEELDKWAKIAAYGHEVGK |
| Q4VXU2 | Y291 | Sugiyama | PABPC1L C20orf119 | ERQNELKRRFEQMKQDRLRRyQGVNLyVKNLDDSIDDDKLR |
| Q4VXU2 | Y297 | Sugiyama | PABPC1L C20orf119 | KRRFEQMKQDRLRRyQGVNLyVKNLDDSIDDDKLRKEFSPY |
| Q562R1 | S240 | Sugiyama | ACTBL2 | VALDFEQEMVRAAAssSPERsyELPDGQVItIGNERFRCPE |
| Q562R1 | Y241 | Sugiyama | ACTBL2 | ALDFEQEMVRAAAssSPERsyELPDGQVItIGNERFRCPEA |
| Q58FF6 | Y167 | Sugiyama | HSP90AB4P | GEPIDRDTKVILHLKEDQtEyLEERWVKEVVKKHPQFIGCL |
| Q58FF6 | Y32 | Sugiyama | HSP90AB4P | KEIFLQELISNASDALDKIRyEsLtDPsKLDGGKELKIDII |
| Q58FF7 | Y171 | Sugiyama | HSP90AB3P HSP90BC | GEPIGRGTKVILHLKEDQtEyLEERRVKEVVKKHsQFIGyP |
| Q58FF7 | Y56 | Sugiyama | HSP90AB3P HSP90BC | EEIFLQELISNASDALDKIRyEsLtDPsKLDsGKELKIDII |
| Q58FF8 | Y198 | Sugiyama | HSP90AB2P HSP90BB | DEEDDsGKDKKKKTKKIKEKyIDQEELNKTKPIWTRNTEDI |
| Q58FF8 | Y260 | Sugiyama | HSP90AB2P HSP90BB | VRYFSVEEYVSRMKEIQKsIyyItGEsKEQVANSAFVEQVW |
| Q58FF8 | Y261 | Sugiyama | HSP90AB2P HSP90BB | RYFSVEEYVSRMKEIQKsIyyItGEsKEQVANSAFVEQVWK |
| Q58FF8 | Y56 | Sugiyama | HSP90AB2P HSP90BB | KEIFLWELISNASDALDKIRyEsLtDPsKLDsGKELKIDII |
| Q58FG0 | Y177 | Sugiyama | HSP90AA5P HSP90AE | GQLEELKDSRRVMKANQKHIyyItGETKDQVANSAFVECLQ |
| Q58FG0 | Y178 | Sugiyama | HSP90AA5P HSP90AE | QLEELKDSRRVMKANQKHIyyItGETKDQVANSAFVECLQK |
| Q6S8J3 | S939 | Sugiyama | POTEE A26C1A POTE2 | VALDFEQEMAtAAssssLEKsyELPDGQVItIGNERFRCPE |
| Q6S8J3 | Y1062 | Sugiyama | POTEE A26C1A POTE2 | GGSILASLSTFQQMWISKQEyDEsGPsIVHRKCF_______ |
| Q6S8J3 | Y940 | Sugiyama | POTEE A26C1A POTE2 | ALDFEQEMAtAAssssLEKsyELPDGQVItIGNERFRCPEA |
| Q71U36 | Y432 | Sugiyama | TUBA1A TUBA3 | GMEEGEFSEAREDMAALEKDyEEVGVDsVEGEGEEEGEEy_ |
| Q7KZF4 | Y476 | Sugiyama | SND1 TDRD11 | SKGLATVIRYRQDDDQRssHyDELLAAEARAIKNGKGLHSK |
| Q8N0Y7 | S137 | Sugiyama | PGAM4 PGAM3 | RsyDVPPPPMEPDHPFysNIsKDRRYADLTEDQLPSYESPK |
| Q8N0Y7 | Y119 | Sugiyama | PGAM4 PGAM3 | NKAETAAKHGEAQVKIWRRsyDVPPPPMEPDHPFysNIsKD |
| Q8N0Y7 | Y92 | Sugiyama | PGAM4 PGAM3 | DAIDQMWLPVVRTWRLNERHyGGLtGLNKAETAAKHGEAQV |
| Q8NBS9 | T248 | Sugiyama | TXNDC5 TLP46 UNQ364/PRO700 | EQLALGLEHSETVKIGKVDCtQHyELCsGNQVRGyPtLLWF |
| Q8NI22 | Y135 | Sugiyama | MCFD2 SDNSF | DELINIIDGVLRDDDKNNDGyIDyAEFAKSLQ_________ |
| Q8NI22 | Y138 | Sugiyama | MCFD2 SDNSF | INIIDGVLRDDDKNNDGyIDyAEFAKSLQ____________ |
| Q8TEW0 | S386 | Sugiyama | PARD3 PAR3 PAR3A | YEQLSQSEKNNyyssRFsPDsQyIDNRSVNSAGLHTVQRAP |
| Q92598 | Y641 | Sugiyama | HSPH1 HSP105 HSP110 KIAA0201 | MIMQDKLEKERNDAKNAVEEyVyEFRDKLCGPYEKFICEQD |
| Q92598 | Y643 | Sugiyama | HSPH1 HSP105 HSP110 KIAA0201 | MQDKLEKERNDAKNAVEEyVyEFRDKLCGPYEKFICEQDHQ |
| Q969T4 | Y91 | Sugiyama | UBE2E3 UBCE4 UBCH9 | AEITLDPPPNCSAGPKGDNIyEWRSTILGPPGSVYEGGVFF |
| Q96LR5 | Y85 | Sugiyama | UBE2E2 UBCH8 | AEITLDPPPNCSAGPKGDNIyEWRSTILGPPGSVYEGGVFF |
| Q99733 | Y95 | Sugiyama | NAP1L4 NAP2 | VRCAHIEAKFyEEVHDLERKyAALyQPLFDKRREFItGDVE |
| Q99733 | Y99 | Sugiyama | NAP1L4 NAP2 | HIEAKFyEEVHDLERKyAALyQPLFDKRREFItGDVEPtDA |
| Q9BQE3 | Y432 | Sugiyama | TUBA1C TUBA6 | GMEEGEFSEAREDMAALEKDyEEVGADsADGEDEGEEy___ |
| Q9BRL6 | Y44 | Sugiyama | SRSF8 SFRS2B SRP46 | RtsPDsLRRVFEKYGRVGDVyIPREPHTKAPRGFAFVRFHD |
| Q9BY32 | Y45 | Sugiyama | ITPA C20orf37 My049 OK/SW-cl.9 | QILGDKFPCTLVAQKIDLPEyQGEPDEIsIQKCQEAVRQVQ |
| Q9BYX7 | S239 | Sugiyama | POTEKP ACTBL3 FKSG30 | VALDSEQEMAMAASSSSVEKsyELPDGQVItIGNERFRCPE |
| Q9BYX7 | Y240 | Sugiyama | POTEKP ACTBL3 FKSG30 | ALDSEQEMAMAASSSSVEKsyELPDGQVItIGNERFRCPEA |
| Q9BYX7 | Y362 | Sugiyama | POTEKP ACTBL3 FKSG30 | GGSILASLSTFQQMWISKQEyDEsGPsIVHRKCF_______ |
| Q9HB07 | Y189 | Sugiyama | MYG1 C12orf10 | VEEVDAVDNGISQWAEGEPRyALttTLsARVARLNPTWNHP |
| Q9NP74 | Y174 | Sugiyama | PALMD C1orf11 PALML | RLRKEINEEKEDDEQNRKALyAMEIKVEKDLKTGESTVLSs |
| Q9NVS9 | Y256 | Sugiyama | PNPO | LPtGDsPLGPMTHRGEEDWLyERLAP_______________ |
| Q9UBR2 | Y76 | Sugiyama | CTSZ | YLSPADLPKSWDWRNVDGVNyAsItRNQHIPQYCGSCWAHA |
| Q9UI15 | Y192 | Sugiyama | TAGLN3 NP25 | NVIGLQMGSNKGAsQAGMtGyGMPRQIM_____________ |
| Q9UMX5 | Y65 | Sugiyama | NENF CIR2 SPUF | RLFtEEELARYGGEEEDQPIyLAVKGVVFDVtSGKEFYGRG |
| Q9Y2B0 | Y71 | Sugiyama | CNPY2 MSAP TMEM4 ZSIG9 UNQ1943/PRO4426 | IQMGsFRINPDGsQsVVEVPyARsEAHLtELLEEICDRMKE |
| Q9Y2T7 | Y107 | Sugiyama | YBX2 CSDA3 MSY2 | KPVLAIQVLGTVKWFNVRNGyGFINRNDtKEDVFVHQtAIK |
| Q9Y3D8 | Y31 | Sugiyama | AK6 CINAP AD-004 CGI-137 | TPGVGKTTLGKELASKSGLKyINVGDLAREEQLYDGYDEEY |
| Q9Y3F4 | T109 | Sugiyama | STRAP MAWD UNRIP | VSGDELMTLAHKHIVKtVDFtQDSNyLLtGGQDKLLRIYDL |
| Q9Y4L1 | Y759 | Sugiyama | HYOU1 GRP170 HSPH4 ORP150 | AANsLEAFIFEtQDKLyQPEyQEVsTEEQREEISGKLSAAS |
| Q9Y639 | Y216 | Sugiyama | NPTN SDFR1 SDR1 | KNASNMEYRINKPRAEDsGEyHCVyHFVsAPKANATIEVKA |
| Q9Y639 | Y220 | Sugiyama | NPTN SDFR1 SDR1 | NMEYRINKPRAEDsGEyHCVyHFVsAPKANATIEVKAAPDI |
| Q9Y696 | Y244 | Sugiyama | CLIC4 | AysRDEFtNtCPsDKEVEIAysDVAKRLTK___________ |
Site Promiscuity
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 7.793766e-14 | 13.108 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 2.161604e-13 | 12.665 | 0 | 0 |
| RNA Polymerase I Promoter Opening | R-HSA-73728 | 2.161604e-13 | 12.665 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 4.051204e-13 | 12.392 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 9.726664e-13 | 12.012 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 1.409539e-12 | 11.851 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 1.281975e-12 | 11.892 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 2.180145e-12 | 11.662 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 2.180145e-12 | 11.662 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 3.611778e-12 | 11.442 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 4.606759e-12 | 11.337 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 4.606759e-12 | 11.337 | 0 | 0 |
| Depurination | R-HSA-73927 | 5.842549e-12 | 11.233 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 6.247669e-12 | 11.204 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 7.545742e-12 | 11.122 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 7.622347e-12 | 11.118 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 9.247936e-12 | 11.034 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 9.247936e-12 | 11.034 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 1.090228e-11 | 10.962 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 1.154699e-11 | 10.938 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 1.154699e-11 | 10.938 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 1.774936e-11 | 10.751 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 1.774936e-11 | 10.751 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 2.185918e-11 | 10.660 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 3.274125e-11 | 10.485 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 3.274125e-11 | 10.485 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 3.610001e-11 | 10.442 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 3.983291e-11 | 10.400 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 5.830114e-11 | 10.234 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 6.205192e-11 | 10.207 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 9.144363e-11 | 10.039 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 1.005843e-10 | 9.997 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 1.413986e-10 | 9.850 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 1.423921e-10 | 9.847 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 1.413986e-10 | 9.850 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 1.628708e-10 | 9.788 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 1.686615e-10 | 9.773 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 2.535360e-10 | 9.596 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 2.815066e-10 | 9.551 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 2.940117e-10 | 9.532 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 3.229170e-10 | 9.491 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 3.773817e-10 | 9.423 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 3.662736e-10 | 9.436 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 4.399530e-10 | 9.357 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 4.548285e-10 | 9.342 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 4.734818e-10 | 9.325 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 6.082871e-10 | 9.216 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 5.937280e-10 | 9.226 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 6.749897e-10 | 9.171 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 7.099797e-10 | 9.149 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 7.099797e-10 | 9.149 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 7.768546e-10 | 9.110 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 8.711235e-10 | 9.060 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 8.711235e-10 | 9.060 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 8.711235e-10 | 9.060 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 9.220460e-10 | 9.035 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 9.220460e-10 | 9.035 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 1.053078e-09 | 8.978 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 1.209027e-09 | 8.918 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 1.381539e-09 | 8.860 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 1.808655e-09 | 8.743 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 2.023073e-09 | 8.694 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 1.957205e-09 | 8.708 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 2.711534e-09 | 8.567 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 3.017673e-09 | 8.520 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 3.482272e-09 | 8.458 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 5.061609e-09 | 8.296 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 6.949783e-09 | 8.158 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 6.949783e-09 | 8.158 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 1.084930e-08 | 7.965 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 1.144324e-08 | 7.941 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 1.277256e-08 | 7.894 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 1.315956e-08 | 7.881 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 1.576855e-08 | 7.802 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 1.659541e-08 | 7.780 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 2.037939e-08 | 7.691 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 2.242161e-08 | 7.649 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 3.754908e-08 | 7.425 | 1 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 4.047168e-08 | 7.393 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 4.777130e-08 | 7.321 | 1 | 0 |
| Telomere Maintenance | R-HSA-157579 | 4.870158e-08 | 7.312 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 5.846668e-08 | 7.233 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 6.803659e-08 | 7.167 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 7.638589e-08 | 7.117 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 1.203017e-07 | 6.920 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 1.939632e-07 | 6.712 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 2.235296e-07 | 6.651 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 3.377124e-07 | 6.471 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 3.521316e-07 | 6.453 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 4.381581e-07 | 6.358 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 4.708485e-07 | 6.327 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 5.053566e-07 | 6.296 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 5.988610e-07 | 6.223 | 1 | 0 |
| DNA Replication | R-HSA-69306 | 6.203224e-07 | 6.207 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 6.872803e-07 | 6.163 | 1 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 7.147037e-07 | 6.146 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 7.879715e-07 | 6.103 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 8.741240e-07 | 6.058 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 9.338209e-07 | 6.030 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 1.088283e-06 | 5.963 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 1.643740e-06 | 5.784 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 1.601659e-06 | 5.795 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 2.468428e-06 | 5.608 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 2.807704e-06 | 5.552 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 3.897653e-06 | 5.409 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 4.186050e-06 | 5.378 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 5.087225e-06 | 5.294 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 6.570822e-06 | 5.182 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 8.206556e-06 | 5.086 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 1.167994e-05 | 4.933 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 1.225320e-05 | 4.912 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 1.318568e-05 | 4.880 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 1.947311e-05 | 4.711 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 2.098554e-05 | 4.678 | 1 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 3.237843e-05 | 4.490 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 4.028708e-05 | 4.395 | 1 | 1 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 4.941210e-05 | 4.306 | 1 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 5.523819e-05 | 4.258 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 5.586017e-05 | 4.253 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 5.852554e-05 | 4.233 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 6.183491e-05 | 4.209 | 1 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 6.866875e-05 | 4.163 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in interleukin signaling | R-HSA-8939247 | 7.291087e-05 | 4.137 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in BCR signaling | R-HSA-8939245 | 7.291087e-05 | 4.137 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 9.202292e-05 | 4.036 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 9.971708e-05 | 4.001 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 1.072409e-04 | 3.970 | 0 | 0 |
| Immune System | R-HSA-168256 | 1.524810e-04 | 3.817 | 1 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 1.657645e-04 | 3.781 | 0 | 0 |
| Activation of TRKA receptors | R-HSA-187015 | 2.074262e-04 | 3.683 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 2.587419e-04 | 3.587 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 2.669577e-04 | 3.574 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 2.656293e-04 | 3.576 | 1 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 2.799286e-04 | 3.553 | 0 | 0 |
| Disease | R-HSA-1643685 | 2.616325e-04 | 3.582 | 1 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 2.394915e-04 | 3.621 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 2.590764e-04 | 3.587 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 2.877163e-04 | 3.541 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 2.895474e-04 | 3.538 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 2.921297e-04 | 3.534 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 2.966890e-04 | 3.528 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 2.966890e-04 | 3.528 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 2.966890e-04 | 3.528 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 2.985045e-04 | 3.525 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 3.170892e-04 | 3.499 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 3.239574e-04 | 3.490 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 3.299886e-04 | 3.482 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 3.678952e-04 | 3.434 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 3.843025e-04 | 3.415 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 4.173161e-04 | 3.380 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 4.173161e-04 | 3.380 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 4.173161e-04 | 3.380 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 4.344065e-04 | 3.362 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 5.509266e-04 | 3.259 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 6.721241e-04 | 3.173 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 6.721241e-04 | 3.173 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 5.483171e-04 | 3.261 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 5.483171e-04 | 3.261 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 5.994028e-04 | 3.222 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 6.819928e-04 | 3.166 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 5.509266e-04 | 3.259 | 0 | 0 |
| M Phase | R-HSA-68886 | 6.357865e-04 | 3.197 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 5.509266e-04 | 3.259 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 6.819928e-04 | 3.166 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 6.035197e-04 | 3.219 | 0 | 0 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 8.091025e-04 | 3.092 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 8.091025e-04 | 3.092 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 8.091025e-04 | 3.092 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 8.122897e-04 | 3.090 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 9.519255e-04 | 3.021 | 0 | 0 |
| RUNX3 regulates RUNX1-mediated transcription | R-HSA-8951911 | 9.546450e-04 | 3.020 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 9.971095e-04 | 3.001 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 1.015885e-03 | 2.993 | 1 | 1 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 1.219743e-03 | 2.914 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 1.237768e-03 | 2.907 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 1.298680e-03 | 2.886 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 1.322267e-03 | 2.879 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 1.331698e-03 | 2.876 | 0 | 0 |
| TRKA activation by NGF | R-HSA-187042 | 1.480785e-03 | 2.830 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 1.556965e-03 | 2.808 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 1.774385e-03 | 2.751 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 1.851631e-03 | 2.732 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 2.116837e-03 | 2.674 | 0 | 0 |
| FLT3 signaling through SRC family kinases | R-HSA-9706374 | 2.116837e-03 | 2.674 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 2.116837e-03 | 2.674 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 2.116837e-03 | 2.674 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 2.158009e-03 | 2.666 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 2.869178e-03 | 2.542 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 2.872420e-03 | 2.542 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 2.872420e-03 | 2.542 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 2.872420e-03 | 2.542 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 3.073462e-03 | 2.512 | 1 | 0 |
| Signalling to RAS | R-HSA-167044 | 3.201430e-03 | 2.495 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 3.220092e-03 | 2.492 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 3.348112e-03 | 2.475 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 3.360218e-03 | 2.474 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 3.503958e-03 | 2.455 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 3.556342e-03 | 2.449 | 0 | 0 |
| NGF-independant TRKA activation | R-HSA-187024 | 3.708847e-03 | 2.431 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 3.733826e-03 | 2.428 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 3.733826e-03 | 2.428 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 3.756715e-03 | 2.425 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 4.761591e-03 | 2.322 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 5.686326e-03 | 2.245 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 5.711422e-03 | 2.243 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 5.950060e-03 | 2.225 | 1 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 5.952965e-03 | 2.225 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 6.195856e-03 | 2.208 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 6.711501e-03 | 2.173 | 0 | 0 |
| Activated NTRK2 signals through FYN | R-HSA-9032500 | 6.860828e-03 | 2.164 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 6.860828e-03 | 2.164 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 6.860828e-03 | 2.164 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 6.966633e-03 | 2.157 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 6.966633e-03 | 2.157 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 7.262572e-03 | 2.139 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 7.262572e-03 | 2.139 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 7.262572e-03 | 2.139 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 7.839694e-03 | 2.106 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 7.839694e-03 | 2.106 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 8.105939e-03 | 2.091 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 8.443141e-03 | 2.073 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 8.491922e-03 | 2.071 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 8.491922e-03 | 2.071 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 8.491922e-03 | 2.071 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 8.904679e-03 | 2.050 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 9.330326e-03 | 2.030 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 9.444524e-03 | 2.025 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 1.087439e-02 | 1.964 | 0 | 0 |
| Drug resistance of FLT3 mutants | R-HSA-9702506 | 1.105473e-02 | 1.956 | 0 | 0 |
| Drug resistance of KIT mutants | R-HSA-9669937 | 1.105473e-02 | 1.956 | 0 | 0 |
| Drug resistance of PDGFR mutants | R-HSA-9674415 | 1.105473e-02 | 1.956 | 0 | 0 |
| KIT mutants bind TKIs | R-HSA-9669921 | 1.105473e-02 | 1.956 | 0 | 0 |
| PDGFR mutants bind TKIs | R-HSA-9674428 | 1.105473e-02 | 1.956 | 0 | 0 |
| FLT3 mutants bind TKIs | R-HSA-9702509 | 1.105473e-02 | 1.956 | 0 | 0 |
| tandutinib-resistant FLT3 mutants | R-HSA-9702636 | 1.105473e-02 | 1.956 | 0 | 0 |
| Imatinib-resistant KIT mutants | R-HSA-9669917 | 1.105473e-02 | 1.956 | 0 | 0 |
| Masitinib-resistant KIT mutants | R-HSA-9669924 | 1.105473e-02 | 1.956 | 0 | 0 |
| Regorafenib-resistant KIT mutants | R-HSA-9669929 | 1.105473e-02 | 1.956 | 0 | 0 |
| Dasatinib-resistant KIT mutants | R-HSA-9669914 | 1.105473e-02 | 1.956 | 0 | 0 |
| tamatinib-resistant FLT3 mutants | R-HSA-9703009 | 1.105473e-02 | 1.956 | 0 | 0 |
| Nilotinib-resistant KIT mutants | R-HSA-9669926 | 1.105473e-02 | 1.956 | 0 | 0 |
| Sorafenib-resistant PDGFR mutants | R-HSA-9674404 | 1.105473e-02 | 1.956 | 0 | 0 |
| pexidartinib-resistant FLT3 mutants | R-HSA-9702605 | 1.105473e-02 | 1.956 | 0 | 0 |
| crenolanib-resistant FLT3 mutants | R-HSA-9702581 | 1.105473e-02 | 1.956 | 0 | 0 |
| lestaurtinib-resistant FLT3 mutants | R-HSA-9702596 | 1.105473e-02 | 1.956 | 0 | 0 |
| semaxanib-resistant FLT3 mutants | R-HSA-9702577 | 1.105473e-02 | 1.956 | 0 | 0 |
| Imatinib-resistant PDGFR mutants | R-HSA-9674396 | 1.105473e-02 | 1.956 | 0 | 0 |
| sorafenib-resistant FLT3 mutants | R-HSA-9702624 | 1.105473e-02 | 1.956 | 0 | 0 |
| KW2449-resistant FLT3 mutants | R-HSA-9702569 | 1.105473e-02 | 1.956 | 0 | 0 |
| sunitinib-resistant FLT3 mutants | R-HSA-9702632 | 1.105473e-02 | 1.956 | 0 | 0 |
| Regorafenib-resistant PDGFR mutants | R-HSA-9674403 | 1.105473e-02 | 1.956 | 0 | 0 |
| midostaurin-resistant FLT3 mutants | R-HSA-9702600 | 1.105473e-02 | 1.956 | 0 | 0 |
| linifanib-resistant FLT3 mutants | R-HSA-9702998 | 1.105473e-02 | 1.956 | 0 | 0 |
| quizartinib-resistant FLT3 mutants | R-HSA-9702620 | 1.105473e-02 | 1.956 | 0 | 0 |
| ponatinib-resistant FLT3 mutants | R-HSA-9702614 | 1.105473e-02 | 1.956 | 0 | 0 |
| Sunitinib-resistant KIT mutants | R-HSA-9669934 | 1.105473e-02 | 1.956 | 0 | 0 |
| gilteritinib-resistant FLT3 mutants | R-HSA-9702590 | 1.105473e-02 | 1.956 | 0 | 0 |
| Sunitinib-resistant PDGFR mutants | R-HSA-9674401 | 1.105473e-02 | 1.956 | 0 | 0 |
| Sorafenib-resistant KIT mutants | R-HSA-9669936 | 1.105473e-02 | 1.956 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 1.112496e-02 | 1.954 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 1.399935e-02 | 1.854 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 1.399935e-02 | 1.854 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 1.746399e-02 | 1.758 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 1.781249e-02 | 1.749 | 1 | 1 |
| MAP2K and MAPK activation | R-HSA-5674135 | 1.781249e-02 | 1.749 | 1 | 1 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 1.746399e-02 | 1.758 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 1.342337e-02 | 1.872 | 1 | 1 |
| GPVI-mediated activation cascade | R-HSA-114604 | 1.262955e-02 | 1.899 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 1.399935e-02 | 1.854 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 1.520489e-02 | 1.818 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 1.520489e-02 | 1.818 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 1.597243e-02 | 1.797 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 1.746399e-02 | 1.758 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 1.262955e-02 | 1.899 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 1.432734e-02 | 1.844 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 1.931859e-02 | 1.714 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 1.931859e-02 | 1.714 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 1.976577e-02 | 1.704 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 2.012660e-02 | 1.696 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 2.012660e-02 | 1.696 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 2.079989e-02 | 1.682 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 2.125204e-02 | 1.673 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 2.183261e-02 | 1.661 | 0 | 0 |
| Activation and oligomerization of BAK protein | R-HSA-111452 | 2.198793e-02 | 1.658 | 0 | 0 |
| Drug-mediated inhibition of MET activation | R-HSA-9734091 | 2.198793e-02 | 1.658 | 0 | 0 |
| SARS-CoV-1 targets PDZ proteins in cell-cell junction | R-HSA-9692912 | 2.198793e-02 | 1.658 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 2.253074e-02 | 1.647 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 2.290867e-02 | 1.640 | 1 | 1 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 2.290867e-02 | 1.640 | 1 | 1 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 2.290867e-02 | 1.640 | 1 | 1 |
| Signaling by RAS mutants | R-HSA-6802949 | 2.290867e-02 | 1.640 | 1 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 2.534775e-02 | 1.596 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 2.630729e-02 | 1.580 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 2.750621e-02 | 1.561 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 2.750621e-02 | 1.561 | 1 | 1 |
| Nephron development | R-HSA-9831926 | 2.750621e-02 | 1.561 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 2.750621e-02 | 1.561 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 2.784970e-02 | 1.555 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 2.871634e-02 | 1.542 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 3.203508e-02 | 1.494 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 3.203508e-02 | 1.494 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 3.253783e-02 | 1.488 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 3.257662e-02 | 1.487 | 0 | 0 |
| Signaling by extracellular domain mutants of KIT | R-HSA-9680187 | 3.280092e-02 | 1.484 | 0 | 0 |
| Signaling by juxtamembrane domain KIT mutants | R-HSA-9669935 | 3.280092e-02 | 1.484 | 0 | 0 |
| Signaling by kinase domain mutants of KIT | R-HSA-9669933 | 3.280092e-02 | 1.484 | 0 | 0 |
| Transport of connexins along the secretory pathway | R-HSA-190827 | 3.280092e-02 | 1.484 | 0 | 0 |
| Oligomerization of connexins into connexons | R-HSA-190704 | 3.280092e-02 | 1.484 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 3.328886e-02 | 1.478 | 0 | 0 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 3.440188e-02 | 1.463 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 3.522673e-02 | 1.453 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 3.522673e-02 | 1.453 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 3.661296e-02 | 1.436 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 3.661296e-02 | 1.436 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 3.683457e-02 | 1.434 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 3.683457e-02 | 1.434 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 3.683457e-02 | 1.434 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 3.723593e-02 | 1.429 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 3.802692e-02 | 1.420 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 4.349502e-02 | 1.362 | 0 | 0 |
| BDNF activates NTRK2 (TRKB) signaling | R-HSA-9024909 | 4.349502e-02 | 1.362 | 0 | 0 |
| NTF4 activates NTRK2 (TRKB) signaling | R-HSA-9026357 | 4.349502e-02 | 1.362 | 0 | 0 |
| NTF3 activates NTRK2 (TRKB) signaling | R-HSA-9025046 | 4.349502e-02 | 1.362 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 4.349502e-02 | 1.362 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 4.349502e-02 | 1.362 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 4.349502e-02 | 1.362 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 4.349502e-02 | 1.362 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 4.349502e-02 | 1.362 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 4.349502e-02 | 1.362 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 4.349502e-02 | 1.362 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 4.349502e-02 | 1.362 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 4.349502e-02 | 1.362 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 4.349502e-02 | 1.362 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 4.364082e-02 | 1.360 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 4.395739e-02 | 1.357 | 0 | 0 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 4.451083e-02 | 1.352 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 4.451083e-02 | 1.352 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 4.719008e-02 | 1.326 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 4.726440e-02 | 1.325 | 1 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 4.783685e-02 | 1.320 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 4.868965e-02 | 1.313 | 1 | 1 |
| MET activates PTK2 signaling | R-HSA-8874081 | 4.992688e-02 | 1.302 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 4.992688e-02 | 1.302 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 5.062696e-02 | 1.296 | 0 | 0 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 5.271963e-02 | 1.278 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 5.271963e-02 | 1.278 | 0 | 0 |
| PLC-gamma1 signalling | R-HSA-167021 | 5.407154e-02 | 1.267 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 5.407154e-02 | 1.267 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 5.407154e-02 | 1.267 | 0 | 0 |
| Invadopodia formation | R-HSA-8941237 | 5.407154e-02 | 1.267 | 0 | 0 |
| Signalling to STAT3 | R-HSA-198745 | 5.407154e-02 | 1.267 | 0 | 0 |
| MET activates STAT3 | R-HSA-8875791 | 5.407154e-02 | 1.267 | 0 | 0 |
| Activated NTRK2 signals through PLCG1 | R-HSA-9026527 | 6.453175e-02 | 1.190 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 6.453175e-02 | 1.190 | 0 | 0 |
| NTRK2 activates RAC1 | R-HSA-9032759 | 7.487693e-02 | 1.126 | 0 | 0 |
| FLT3 signaling by CBL mutants | R-HSA-9706377 | 7.487693e-02 | 1.126 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 8.510834e-02 | 1.070 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 8.510834e-02 | 1.070 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 8.510834e-02 | 1.070 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 8.510834e-02 | 1.070 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 8.510834e-02 | 1.070 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in WNT signaling | R-HSA-8939256 | 9.522722e-02 | 1.021 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 9.522722e-02 | 1.021 | 0 | 0 |
| STAT5 Activation | R-HSA-9645135 | 9.522722e-02 | 1.021 | 0 | 0 |
| Activated NTRK2 signals through CDK5 | R-HSA-9032845 | 1.052348e-01 | 0.978 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 1.052348e-01 | 0.978 | 0 | 0 |
| IFNG signaling activates MAPKs | R-HSA-9732724 | 1.052348e-01 | 0.978 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 1.151323e-01 | 0.939 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 1.151323e-01 | 0.939 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 1.151323e-01 | 0.939 | 0 | 0 |
| Activated NTRK2 signals through PI3K | R-HSA-9028335 | 1.151323e-01 | 0.939 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 7.370834e-02 | 1.132 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 9.005729e-02 | 1.045 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 7.583131e-02 | 1.120 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 1.003299e-01 | 0.999 | 1 | 0 |
| RUNX1 regulates estrogen receptor mediated transcription | R-HSA-8931987 | 1.052348e-01 | 0.978 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 8.608598e-02 | 1.065 | 1 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 1.052348e-01 | 0.978 | 0 | 0 |
| Reelin signalling pathway | R-HSA-8866376 | 7.487693e-02 | 1.126 | 0 | 0 |
| Signaling by MST1 | R-HSA-8852405 | 8.510834e-02 | 1.070 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of keratinocytes | R-HSA-8939242 | 1.151323e-01 | 0.939 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 6.141820e-02 | 1.212 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 7.689496e-02 | 1.114 | 0 | 0 |
| MET Receptor Activation | R-HSA-6806942 | 9.522722e-02 | 1.021 | 0 | 0 |
| RUNX2 regulates genes involved in differentiation of myeloid cells | R-HSA-8941333 | 6.453175e-02 | 1.190 | 0 | 0 |
| Release of apoptotic factors from the mitochondria | R-HSA-111457 | 8.510834e-02 | 1.070 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 1.031559e-01 | 0.987 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 8.339557e-02 | 1.079 | 0 | 0 |
| p75NTR negatively regulates cell cycle via SC1 | R-HSA-193670 | 6.453175e-02 | 1.190 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 8.510834e-02 | 1.070 | 0 | 0 |
| VLDL clearance | R-HSA-8964046 | 1.052348e-01 | 0.978 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 7.353275e-02 | 1.134 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 1.038239e-01 | 0.984 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 1.003299e-01 | 0.999 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 1.144990e-01 | 0.941 | 0 | 0 |
| Netrin mediated repulsion signals | R-HSA-418886 | 1.052348e-01 | 0.978 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 8.510834e-02 | 1.070 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 8.510834e-02 | 1.070 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 1.151323e-01 | 0.939 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 6.220143e-02 | 1.206 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 5.846681e-02 | 1.233 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 6.141820e-02 | 1.212 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 8.012448e-02 | 1.096 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 8.012448e-02 | 1.096 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 5.886618e-02 | 1.230 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 6.430023e-02 | 1.192 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 6.288622e-02 | 1.201 | 1 | 0 |
| Innate Immune System | R-HSA-168249 | 7.417011e-02 | 1.130 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 7.583131e-02 | 1.120 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 1.151323e-01 | 0.939 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 1.074301e-01 | 0.969 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 6.218740e-02 | 1.206 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 1.038239e-01 | 0.984 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 1.144990e-01 | 0.941 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 1.144990e-01 | 0.941 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 6.746922e-02 | 1.171 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 1.013655e-01 | 0.994 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 1.105091e-01 | 0.957 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 1.176398e-01 | 0.929 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 1.187901e-01 | 0.925 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 1.197168e-01 | 0.922 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 1.217655e-01 | 0.914 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 1.224592e-01 | 0.912 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 1.248958e-01 | 0.903 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 1.249209e-01 | 0.903 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 1.249209e-01 | 0.903 | 0 | 0 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | R-HSA-428542 | 1.249209e-01 | 0.903 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 1.249209e-01 | 0.903 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 1.263368e-01 | 0.898 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 1.328683e-01 | 0.877 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 1.346019e-01 | 0.871 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 1.346019e-01 | 0.871 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 1.346019e-01 | 0.871 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 1.346019e-01 | 0.871 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 1.346019e-01 | 0.871 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 1.346019e-01 | 0.871 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 1.346019e-01 | 0.871 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 1.441698e-01 | 0.841 | 0 | 0 |
| Conjugation of benzoate with glycine | R-HSA-177135 | 1.441763e-01 | 0.841 | 0 | 0 |
| RHOBTB3 ATPase cycle | R-HSA-9706019 | 1.441763e-01 | 0.841 | 0 | 0 |
| Dissolution of Fibrin Clot | R-HSA-75205 | 1.441763e-01 | 0.841 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 1.458724e-01 | 0.836 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 1.475814e-01 | 0.831 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 1.475814e-01 | 0.831 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 1.501809e-01 | 0.823 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 1.501809e-01 | 0.823 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperone genes | R-HSA-381183 | 1.536454e-01 | 0.813 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 1.598004e-01 | 0.796 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 1.626300e-01 | 0.789 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 1.630103e-01 | 0.788 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 1.630103e-01 | 0.788 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 1.630103e-01 | 0.788 | 0 | 0 |
| Conjugation of salicylate with glycine | R-HSA-177128 | 1.630103e-01 | 0.788 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 1.630103e-01 | 0.788 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 1.630103e-01 | 0.788 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 1.630103e-01 | 0.788 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 1.630103e-01 | 0.788 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 1.630103e-01 | 0.788 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 1.634777e-01 | 0.787 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 1.650946e-01 | 0.782 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 1.668786e-01 | 0.778 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 1.668786e-01 | 0.778 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 1.711668e-01 | 0.767 | 0 | 0 |
| RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) | R-HSA-8877330 | 1.722721e-01 | 0.764 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 1.722721e-01 | 0.764 | 0 | 0 |
| IL-6-type cytokine receptor ligand interactions | R-HSA-6788467 | 1.722721e-01 | 0.764 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 1.722721e-01 | 0.764 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperones | R-HSA-381033 | 1.722721e-01 | 0.764 | 0 | 0 |
| Platelet Adhesion to exposed collagen | R-HSA-75892 | 1.722721e-01 | 0.764 | 0 | 0 |
| Kinesins | R-HSA-983189 | 1.752609e-01 | 0.756 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 1.763118e-01 | 0.754 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 1.769403e-01 | 0.752 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 1.769403e-01 | 0.752 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 1.814320e-01 | 0.741 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 1.868983e-01 | 0.728 | 1 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 1.904912e-01 | 0.720 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 1.904912e-01 | 0.720 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 1.904912e-01 | 0.720 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 1.904912e-01 | 0.720 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 1.904912e-01 | 0.720 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 1.904912e-01 | 0.720 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 1.904912e-01 | 0.720 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 1.904912e-01 | 0.720 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 1.904912e-01 | 0.720 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 1.911711e-01 | 0.719 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 1.951791e-01 | 0.710 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 1.994506e-01 | 0.700 | 1 | 1 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 1.994506e-01 | 0.700 | 0 | 0 |
| Defective GALNT12 causes CRCS1 | R-HSA-5083636 | 1.994506e-01 | 0.700 | 0 | 0 |
| Defective GALNT3 causes HFTC | R-HSA-5083625 | 1.994506e-01 | 0.700 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 1.994506e-01 | 0.700 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 1.994506e-01 | 0.700 | 0 | 0 |
| Differentiation of T cells | R-HSA-9945266 | 1.994506e-01 | 0.700 | 0 | 0 |
| Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) | R-HSA-9942503 | 1.994506e-01 | 0.700 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 2.032263e-01 | 0.692 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 2.083114e-01 | 0.681 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 2.083114e-01 | 0.681 | 0 | 0 |
| STAT5 activation downstream of FLT3 ITD mutants | R-HSA-9702518 | 2.083114e-01 | 0.681 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 2.083114e-01 | 0.681 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 2.113104e-01 | 0.675 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 2.136736e-01 | 0.670 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 2.170746e-01 | 0.663 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 2.170746e-01 | 0.663 | 0 | 0 |
| Defective C1GALT1C1 causes TNPS | R-HSA-5083632 | 2.170746e-01 | 0.663 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 2.170746e-01 | 0.663 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 2.170746e-01 | 0.663 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 2.170746e-01 | 0.663 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 2.257414e-01 | 0.646 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 2.257414e-01 | 0.646 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 2.257414e-01 | 0.646 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 2.257414e-01 | 0.646 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 2.257414e-01 | 0.646 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 2.257414e-01 | 0.646 | 0 | 0 |
| Apoptotic factor-mediated response | R-HSA-111471 | 2.257414e-01 | 0.646 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 2.257414e-01 | 0.646 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 2.275679e-01 | 0.643 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 2.276727e-01 | 0.643 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 2.279439e-01 | 0.642 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 2.343128e-01 | 0.630 | 0 | 0 |
| Conjugation of carboxylic acids | R-HSA-159424 | 2.343128e-01 | 0.630 | 0 | 0 |
| Amino Acid conjugation | R-HSA-156587 | 2.343128e-01 | 0.630 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 2.343128e-01 | 0.630 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 2.357310e-01 | 0.628 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 2.395133e-01 | 0.621 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 2.398189e-01 | 0.620 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 2.405612e-01 | 0.619 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 2.427899e-01 | 0.615 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 2.427899e-01 | 0.615 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 2.511736e-01 | 0.600 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 2.511736e-01 | 0.600 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 2.511736e-01 | 0.600 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 2.514540e-01 | 0.600 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 2.594649e-01 | 0.586 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 2.594649e-01 | 0.586 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 2.644005e-01 | 0.578 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 2.676650e-01 | 0.572 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 2.676650e-01 | 0.572 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 2.676650e-01 | 0.572 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 2.676650e-01 | 0.572 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 2.723295e-01 | 0.565 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 2.753030e-01 | 0.560 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 2.757748e-01 | 0.559 | 0 | 0 |
| Termination of O-glycan biosynthesis | R-HSA-977068 | 2.757748e-01 | 0.559 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 2.757748e-01 | 0.559 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 2.757748e-01 | 0.559 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 2.767017e-01 | 0.558 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 2.837953e-01 | 0.547 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 2.837953e-01 | 0.547 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 2.837953e-01 | 0.547 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 2.837953e-01 | 0.547 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 2.848971e-01 | 0.545 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 2.873177e-01 | 0.542 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 2.889918e-01 | 0.539 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 2.889918e-01 | 0.539 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 2.917274e-01 | 0.535 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 2.917274e-01 | 0.535 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 2.930839e-01 | 0.533 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 2.933414e-01 | 0.533 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 2.995722e-01 | 0.523 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 2.995722e-01 | 0.523 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 3.073306e-01 | 0.512 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 3.073306e-01 | 0.512 | 1 | 1 |
| Triglyceride biosynthesis | R-HSA-75109 | 3.073306e-01 | 0.512 | 0 | 0 |
| Synthesis of PE | R-HSA-1483213 | 3.073306e-01 | 0.512 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 3.094172e-01 | 0.509 | 0 | 0 |
| Protein folding | R-HSA-391251 | 3.134897e-01 | 0.504 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 3.134897e-01 | 0.504 | 0 | 0 |
| ATF4 activates genes in response to endoplasmic reticulum stress | R-HSA-380994 | 3.150035e-01 | 0.502 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 3.150035e-01 | 0.502 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 3.150035e-01 | 0.502 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 3.225919e-01 | 0.491 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 3.225919e-01 | 0.491 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 3.235574e-01 | 0.490 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 3.300967e-01 | 0.481 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 3.300967e-01 | 0.481 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 3.300967e-01 | 0.481 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 3.300967e-01 | 0.481 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 3.337681e-01 | 0.477 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 3.337681e-01 | 0.477 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 3.375188e-01 | 0.472 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 3.375188e-01 | 0.472 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 3.375188e-01 | 0.472 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 3.448591e-01 | 0.462 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 3.448591e-01 | 0.462 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 3.448591e-01 | 0.462 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 3.521185e-01 | 0.453 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 3.521185e-01 | 0.453 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 3.521185e-01 | 0.453 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 3.521185e-01 | 0.453 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 3.521185e-01 | 0.453 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 3.521185e-01 | 0.453 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 3.521185e-01 | 0.453 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 3.521185e-01 | 0.453 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 3.521185e-01 | 0.453 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 3.592980e-01 | 0.445 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 3.592980e-01 | 0.445 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 3.592980e-01 | 0.445 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 3.663983e-01 | 0.436 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 3.663983e-01 | 0.436 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 3.663983e-01 | 0.436 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 3.663983e-01 | 0.436 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 3.663983e-01 | 0.436 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 3.663983e-01 | 0.436 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 3.698053e-01 | 0.432 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 3.734204e-01 | 0.428 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 3.734204e-01 | 0.428 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 3.734204e-01 | 0.428 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 3.734204e-01 | 0.428 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 3.803651e-01 | 0.420 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 3.803651e-01 | 0.420 | 0 | 0 |
| Translation | R-HSA-72766 | 3.844144e-01 | 0.415 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 3.872332e-01 | 0.412 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 3.872332e-01 | 0.412 | 0 | 0 |
| SLC-mediated transport of organic cations | R-HSA-549127 | 3.872332e-01 | 0.412 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 3.912625e-01 | 0.408 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 3.940256e-01 | 0.404 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 4.007432e-01 | 0.397 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 4.007432e-01 | 0.397 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 4.007432e-01 | 0.397 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 4.007432e-01 | 0.397 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 4.011868e-01 | 0.397 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 4.011868e-01 | 0.397 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 4.073867e-01 | 0.390 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 4.073867e-01 | 0.390 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 4.073867e-01 | 0.390 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 4.073867e-01 | 0.390 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 4.073867e-01 | 0.390 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 4.073867e-01 | 0.390 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 4.073867e-01 | 0.390 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 4.073867e-01 | 0.390 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 4.073867e-01 | 0.390 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 4.089201e-01 | 0.388 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 4.139569e-01 | 0.383 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 4.139569e-01 | 0.383 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 4.204547e-01 | 0.376 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 4.204547e-01 | 0.376 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 4.204547e-01 | 0.376 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 4.204547e-01 | 0.376 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 4.268809e-01 | 0.370 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 4.332362e-01 | 0.363 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 4.395214e-01 | 0.357 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 4.430978e-01 | 0.354 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 4.457373e-01 | 0.351 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 4.457373e-01 | 0.351 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 4.487223e-01 | 0.348 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 4.505460e-01 | 0.346 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 4.518847e-01 | 0.345 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 4.518847e-01 | 0.345 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 4.518847e-01 | 0.345 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 4.518847e-01 | 0.345 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 4.542491e-01 | 0.343 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 4.573690e-01 | 0.340 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 4.579642e-01 | 0.339 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 4.579642e-01 | 0.339 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 4.579642e-01 | 0.339 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 4.673395e-01 | 0.330 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 4.699228e-01 | 0.328 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 4.758034e-01 | 0.323 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 4.758034e-01 | 0.323 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 4.873706e-01 | 0.312 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 4.873706e-01 | 0.312 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 4.873706e-01 | 0.312 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 4.930587e-01 | 0.307 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 4.930587e-01 | 0.307 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 4.986839e-01 | 0.302 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 4.986839e-01 | 0.302 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 5.042472e-01 | 0.297 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 5.042472e-01 | 0.297 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 5.097490e-01 | 0.293 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 5.097490e-01 | 0.293 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 5.114842e-01 | 0.291 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 5.151901e-01 | 0.288 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 5.151901e-01 | 0.288 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 5.205711e-01 | 0.284 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 5.258928e-01 | 0.279 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 5.258928e-01 | 0.279 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 5.258928e-01 | 0.279 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 5.258928e-01 | 0.279 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 5.311557e-01 | 0.275 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 5.311557e-01 | 0.275 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 5.311557e-01 | 0.275 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 5.311557e-01 | 0.275 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 5.311557e-01 | 0.275 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 5.311557e-01 | 0.275 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 5.311557e-01 | 0.275 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 5.319184e-01 | 0.274 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 5.319184e-01 | 0.274 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 5.363605e-01 | 0.271 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 5.363605e-01 | 0.271 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 5.363605e-01 | 0.271 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 5.415078e-01 | 0.266 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 5.415078e-01 | 0.266 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 5.415078e-01 | 0.266 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 5.415078e-01 | 0.266 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 5.415078e-01 | 0.266 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 5.465983e-01 | 0.262 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 5.490817e-01 | 0.260 | 0 | 0 |
| CD22 mediated BCR regulation | R-HSA-5690714 | 5.516326e-01 | 0.258 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 5.550168e-01 | 0.256 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 5.646680e-01 | 0.248 | 0 | 0 |
| O-linked glycosylation of mucins | R-HSA-913709 | 5.712200e-01 | 0.243 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 5.712200e-01 | 0.243 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 5.712200e-01 | 0.243 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 5.741691e-01 | 0.241 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 5.741691e-01 | 0.241 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 5.773026e-01 | 0.239 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 5.804194e-01 | 0.236 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 5.804194e-01 | 0.236 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 5.853500e-01 | 0.233 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 5.853500e-01 | 0.233 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 5.853500e-01 | 0.233 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 5.853500e-01 | 0.233 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 5.899563e-01 | 0.229 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 5.945118e-01 | 0.226 | 0 | 0 |
| Aspirin ADME | R-HSA-9749641 | 5.945118e-01 | 0.226 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 5.990169e-01 | 0.223 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 5.990169e-01 | 0.223 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 5.990169e-01 | 0.223 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 6.078783e-01 | 0.216 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 6.122357e-01 | 0.213 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 6.151599e-01 | 0.211 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 6.165449e-01 | 0.210 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 6.165449e-01 | 0.210 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 6.173500e-01 | 0.209 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 6.208065e-01 | 0.207 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 6.250211e-01 | 0.204 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 6.291890e-01 | 0.201 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 6.364469e-01 | 0.196 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 6.373872e-01 | 0.196 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 6.474725e-01 | 0.189 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 6.493477e-01 | 0.188 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 6.532467e-01 | 0.185 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 6.571026e-01 | 0.182 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 6.609158e-01 | 0.180 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 6.646869e-01 | 0.177 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 6.721044e-01 | 0.173 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 6.724982e-01 | 0.172 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 6.757517e-01 | 0.170 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 6.793587e-01 | 0.168 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 6.814880e-01 | 0.167 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 6.899419e-01 | 0.161 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 6.933919e-01 | 0.159 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 6.933919e-01 | 0.159 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 6.968037e-01 | 0.157 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 6.968037e-01 | 0.157 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 7.072240e-01 | 0.150 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 7.100775e-01 | 0.149 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 7.133047e-01 | 0.147 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 7.164961e-01 | 0.145 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 7.164961e-01 | 0.145 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 7.164961e-01 | 0.145 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 7.173723e-01 | 0.144 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 7.196522e-01 | 0.143 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 7.227733e-01 | 0.141 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 7.227733e-01 | 0.141 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 7.349161e-01 | 0.134 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 7.349161e-01 | 0.134 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 7.378682e-01 | 0.132 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 7.378682e-01 | 0.132 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 7.435938e-01 | 0.129 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 7.436748e-01 | 0.129 | 1 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 7.465299e-01 | 0.127 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 7.493534e-01 | 0.125 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 7.618767e-01 | 0.118 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 7.630085e-01 | 0.117 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 7.648230e-01 | 0.116 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 7.656494e-01 | 0.116 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 7.682610e-01 | 0.114 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 7.682610e-01 | 0.114 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 7.682610e-01 | 0.114 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 7.733978e-01 | 0.112 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 7.733978e-01 | 0.112 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 7.774156e-01 | 0.109 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 7.808915e-01 | 0.107 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 7.808915e-01 | 0.107 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 7.857498e-01 | 0.105 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 7.952744e-01 | 0.099 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 8.063199e-01 | 0.093 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 8.084806e-01 | 0.092 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 8.084806e-01 | 0.092 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 8.209505e-01 | 0.086 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 8.229489e-01 | 0.085 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 8.249250e-01 | 0.084 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 8.288118e-01 | 0.082 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 8.315588e-01 | 0.080 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 8.344817e-01 | 0.079 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 8.363298e-01 | 0.078 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 8.435194e-01 | 0.074 | 0 | 0 |
| S Phase | R-HSA-69242 | 8.435194e-01 | 0.074 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 8.469955e-01 | 0.072 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 8.520662e-01 | 0.070 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 8.601487e-01 | 0.065 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 8.617117e-01 | 0.065 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 8.668670e-01 | 0.062 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 8.692700e-01 | 0.061 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 8.736062e-01 | 0.059 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 8.791662e-01 | 0.056 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 8.791662e-01 | 0.056 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 8.933986e-01 | 0.049 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 8.967787e-01 | 0.047 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 8.990770e-01 | 0.046 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 9.013244e-01 | 0.045 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 9.013244e-01 | 0.045 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 9.024293e-01 | 0.045 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 9.035220e-01 | 0.044 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 9.046025e-01 | 0.044 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.166667e-01 | 0.038 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 9.255521e-01 | 0.034 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 9.255521e-01 | 0.034 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 9.288365e-01 | 0.032 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 9.296349e-01 | 0.032 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 9.405944e-01 | 0.027 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 9.406453e-01 | 0.027 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 9.451105e-01 | 0.025 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 9.498550e-01 | 0.022 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 9.586258e-01 | 0.018 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 9.662540e-01 | 0.015 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 9.788044e-01 | 0.009 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 9.790438e-01 | 0.009 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 9.909757e-01 | 0.004 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.919493e-01 | 0.004 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 9.935940e-01 | 0.003 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 9.953504e-01 | 0.002 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 9.958537e-01 | 0.002 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 9.978699e-01 | 0.001 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 9.991588e-01 | 0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 9.992883e-01 | 0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 9.999724e-01 | 0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | 0.000 | 0 | 0 |
Top15 pathways (red highlights are reference pathways)
Compared with reference pathways
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Cell-Cell communication | R-HSA-1500931 | 2.673950e-11 | 10.573 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 2.716272e-11 | 10.566 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 2.716272e-11 | 10.566 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 4.506495e-11 | 10.346 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 7.741652e-11 | 10.111 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 1.697636e-10 | 9.770 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 5.663019e-10 | 9.247 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 1.309894e-09 | 8.883 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 1.213436e-09 | 8.916 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 5.671535e-09 | 8.246 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 7.860493e-09 | 8.105 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 9.789870e-09 | 8.009 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 9.789870e-09 | 8.009 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 1.119016e-08 | 7.951 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 1.404336e-08 | 7.853 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 3.930742e-08 | 7.406 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 9.247259e-08 | 7.034 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 1.022800e-07 | 6.990 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 1.343290e-07 | 6.872 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 1.436435e-07 | 6.843 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 3.531338e-07 | 6.452 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 3.530900e-07 | 6.452 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 7.850094e-07 | 6.105 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 9.464524e-07 | 6.024 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 1.155453e-06 | 5.937 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 1.201867e-06 | 5.920 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 1.365144e-06 | 5.865 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 1.387160e-06 | 5.858 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 1.618200e-06 | 5.791 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 1.613510e-06 | 5.792 | 1 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 1.562472e-06 | 5.806 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 1.622492e-06 | 5.790 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 2.222241e-06 | 5.653 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 2.334256e-06 | 5.632 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 2.461882e-06 | 5.609 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 3.019147e-06 | 5.520 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 4.030596e-06 | 5.395 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 4.122209e-06 | 5.385 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 4.168947e-06 | 5.380 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 5.875698e-06 | 5.231 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 8.048435e-06 | 5.094 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 1.011150e-05 | 4.995 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 1.011150e-05 | 4.995 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 1.087770e-05 | 4.963 | 1 | 1 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 1.591397e-05 | 4.798 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 1.716643e-05 | 4.765 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 1.722185e-05 | 4.764 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 1.871333e-05 | 4.728 | 1 | 1 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 1.871333e-05 | 4.728 | 1 | 1 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 1.871333e-05 | 4.728 | 1 | 1 |
| Signaling by RAS mutants | R-HSA-6802949 | 1.871333e-05 | 4.728 | 1 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 2.015574e-05 | 4.696 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 2.290293e-05 | 4.640 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 2.693890e-05 | 4.570 | 0 | 0 |
| FLT3 signaling through SRC family kinases | R-HSA-9706374 | 3.255577e-05 | 4.487 | 0 | 0 |
| Non-canonical inflammasome activation | R-HSA-9686114 | 3.485630e-05 | 4.458 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 4.294162e-05 | 4.367 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 4.663043e-05 | 4.331 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 5.470775e-05 | 4.262 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 5.475002e-05 | 4.262 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 6.140910e-05 | 4.212 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 6.187335e-05 | 4.208 | 1 | 0 |
| HSF1 activation | R-HSA-3371511 | 7.669850e-05 | 4.115 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 8.536395e-05 | 4.069 | 1 | 1 |
| Signaling by Interleukins | R-HSA-449147 | 7.835884e-05 | 4.106 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 8.619341e-05 | 4.065 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 9.796233e-05 | 4.009 | 1 | 1 |
| Regulation of signaling by CBL | R-HSA-912631 | 1.052172e-04 | 3.978 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 1.159322e-04 | 3.936 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 1.252722e-04 | 3.902 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 1.405512e-04 | 3.852 | 1 | 1 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 1.542676e-04 | 3.812 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 1.603780e-04 | 3.795 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 1.689845e-04 | 3.772 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 1.879844e-04 | 3.726 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 1.879844e-04 | 3.726 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 1.879844e-04 | 3.726 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 1.890573e-04 | 3.723 | 0 | 0 |
| Interleukin-18 signaling | R-HSA-9012546 | 1.934790e-04 | 3.713 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 2.128724e-04 | 3.672 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 2.158915e-04 | 3.666 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 2.234660e-04 | 3.651 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 2.234660e-04 | 3.651 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 2.810685e-04 | 3.551 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 2.593001e-04 | 3.586 | 0 | 0 |
| CASP4 inflammasome assembly | R-HSA-9948001 | 3.147808e-04 | 3.502 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 3.287387e-04 | 3.483 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 3.423736e-04 | 3.465 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 3.564805e-04 | 3.448 | 1 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 3.903243e-04 | 3.409 | 0 | 0 |
| Manipulation of host energy metabolism | R-HSA-9636667 | 4.275573e-04 | 3.369 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 4.283122e-04 | 3.368 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 4.873780e-04 | 3.312 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 4.642350e-04 | 3.333 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 5.529808e-04 | 3.257 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 5.763081e-04 | 3.239 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 5.763081e-04 | 3.239 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 6.070801e-04 | 3.217 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 6.360507e-04 | 3.197 | 0 | 0 |
| Microbial factors inhibit CASP4 activity | R-HSA-9956593 | 6.838906e-04 | 3.165 | 0 | 0 |
| Platelet Adhesion to exposed collagen | R-HSA-75892 | 6.838906e-04 | 3.165 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 7.548461e-04 | 3.122 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 7.548461e-04 | 3.122 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 7.623809e-04 | 3.118 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 9.067450e-04 | 3.043 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 9.379298e-04 | 3.028 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 8.099772e-04 | 3.092 | 1 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 8.541889e-04 | 3.068 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 9.606325e-04 | 3.017 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 1.030693e-03 | 2.987 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 1.073171e-03 | 2.969 | 1 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 1.154515e-03 | 2.938 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 1.324572e-03 | 2.878 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 1.348601e-03 | 2.870 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 1.402025e-03 | 2.853 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 1.486508e-03 | 2.828 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 1.499808e-03 | 2.824 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 1.579924e-03 | 2.801 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 1.625831e-03 | 2.789 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 1.976414e-03 | 2.704 | 0 | 0 |
| Disease | R-HSA-1643685 | 2.306207e-03 | 2.637 | 1 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 2.549678e-03 | 2.594 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 2.338635e-03 | 2.631 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 2.708073e-03 | 2.567 | 1 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 2.367144e-03 | 2.626 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 2.804072e-03 | 2.552 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 2.930191e-03 | 2.533 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 3.050243e-03 | 2.516 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 3.114269e-03 | 2.507 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 3.125248e-03 | 2.505 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 3.171599e-03 | 2.499 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 3.171599e-03 | 2.499 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 3.194656e-03 | 2.496 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 4.260756e-03 | 2.371 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 4.515903e-03 | 2.345 | 0 | 0 |
| Uptake and function of diphtheria toxin | R-HSA-5336415 | 4.540367e-03 | 2.343 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 4.755933e-03 | 2.323 | 0 | 0 |
| Immune System | R-HSA-168256 | 4.812919e-03 | 2.318 | 1 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 4.853513e-03 | 2.314 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 5.094562e-03 | 2.293 | 0 | 0 |
| Activated NTRK2 signals through FYN | R-HSA-9032500 | 5.458538e-03 | 2.263 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 5.458538e-03 | 2.263 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 5.548838e-03 | 2.256 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 5.666357e-03 | 2.247 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 6.454398e-03 | 2.190 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 7.051544e-03 | 2.152 | 1 | 1 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 6.454398e-03 | 2.190 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 5.918969e-03 | 2.228 | 0 | 0 |
| Respiratory syncytial virus genome replication | R-HSA-9834752 | 6.454398e-03 | 2.190 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 7.234782e-03 | 2.141 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 5.885090e-03 | 2.230 | 1 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 6.207748e-03 | 2.207 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 7.526350e-03 | 2.123 | 0 | 0 |
| Assembly and release of respiratory syncytial virus (RSV) virions | R-HSA-9820962 | 7.526350e-03 | 2.123 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 8.076911e-03 | 2.093 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 8.076911e-03 | 2.093 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 1.037901e-02 | 1.984 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 1.118315e-02 | 1.951 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 1.133162e-02 | 1.946 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 1.165825e-02 | 1.933 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 1.206285e-02 | 1.919 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 1.233037e-02 | 1.909 | 1 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 1.254398e-02 | 1.902 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 1.397327e-02 | 1.855 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 1.397327e-02 | 1.855 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 1.447808e-02 | 1.839 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 1.505927e-02 | 1.822 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 1.523805e-02 | 1.817 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 1.546957e-02 | 1.811 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 1.546957e-02 | 1.811 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 1.602018e-02 | 1.795 | 1 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 1.703142e-02 | 1.769 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 1.703142e-02 | 1.769 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 1.765117e-02 | 1.753 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 2.034618e-02 | 1.692 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 2.034618e-02 | 1.692 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 2.209632e-02 | 1.656 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 1.865742e-02 | 1.729 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 2.390648e-02 | 1.621 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 1.937142e-02 | 1.713 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 2.390648e-02 | 1.621 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 1.866138e-02 | 1.729 | 1 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 2.044929e-02 | 1.689 | 1 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 2.034618e-02 | 1.692 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 2.034108e-02 | 1.692 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 2.209632e-02 | 1.656 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 2.034618e-02 | 1.692 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 1.898722e-02 | 1.722 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 2.568585e-02 | 1.590 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 2.577533e-02 | 1.589 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 2.577533e-02 | 1.589 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 2.577533e-02 | 1.589 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 2.577533e-02 | 1.589 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 2.577533e-02 | 1.589 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 2.609794e-02 | 1.583 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 2.770157e-02 | 1.557 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 2.770157e-02 | 1.557 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 2.792081e-02 | 1.554 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 2.968389e-02 | 1.527 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 2.968389e-02 | 1.527 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 3.013273e-02 | 1.521 | 1 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 3.043394e-02 | 1.517 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 3.273539e-02 | 1.485 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 3.464167e-02 | 1.460 | 1 | 0 |
| Translocation of ZAP-70 to Immunological synapse | R-HSA-202430 | 3.595476e-02 | 1.444 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 3.595476e-02 | 1.444 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 3.595476e-02 | 1.444 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 3.595476e-02 | 1.444 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 3.682327e-02 | 1.434 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 3.708478e-02 | 1.431 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 3.814889e-02 | 1.419 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 3.814889e-02 | 1.419 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 3.814889e-02 | 1.419 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 3.873067e-02 | 1.412 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 3.873067e-02 | 1.412 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 3.873067e-02 | 1.412 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 3.873067e-02 | 1.412 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 3.873067e-02 | 1.412 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 3.873067e-02 | 1.412 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 3.873067e-02 | 1.412 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 3.873067e-02 | 1.412 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 3.873067e-02 | 1.412 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 3.873067e-02 | 1.412 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 3.873067e-02 | 1.412 | 0 | 0 |
| Axonal growth stimulation | R-HSA-209563 | 4.817811e-02 | 1.317 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 4.016778e-02 | 1.396 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 4.281916e-02 | 1.368 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 5.427286e-02 | 1.265 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 4.039294e-02 | 1.394 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 4.268572e-02 | 1.370 | 1 | 1 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 4.741285e-02 | 1.324 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 3.873067e-02 | 1.412 | 0 | 0 |
| STAT6-mediated induction of chemokines | R-HSA-3249367 | 4.817811e-02 | 1.317 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 4.817811e-02 | 1.317 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 4.268572e-02 | 1.370 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 3.832727e-02 | 1.416 | 1 | 0 |
| CASP5-mediated substrate cleavage | R-HSA-9960525 | 4.817811e-02 | 1.317 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 4.984494e-02 | 1.302 | 0 | 0 |
| CASP4-mediated substrate cleavage | R-HSA-9960519 | 4.817811e-02 | 1.317 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 4.268572e-02 | 1.370 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 5.232122e-02 | 1.281 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 5.484060e-02 | 1.261 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 4.268572e-02 | 1.370 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 4.268572e-02 | 1.370 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 5.736436e-02 | 1.241 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 4.837818e-02 | 1.315 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 4.483043e-02 | 1.348 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 4.268572e-02 | 1.370 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 5.740202e-02 | 1.241 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 4.984494e-02 | 1.302 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 5.219955e-02 | 1.282 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 4.273142e-02 | 1.369 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 4.016778e-02 | 1.396 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 4.883697e-02 | 1.311 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 4.268572e-02 | 1.370 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 4.502607e-02 | 1.347 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 4.761166e-02 | 1.322 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 5.753327e-02 | 1.240 | 0 | 0 |
| NADE modulates death signalling | R-HSA-205025 | 5.753327e-02 | 1.240 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 5.890930e-02 | 1.230 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 6.021373e-02 | 1.220 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 6.118121e-02 | 1.213 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 6.264672e-02 | 1.203 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 6.291826e-02 | 1.201 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 6.532795e-02 | 1.185 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 6.532795e-02 | 1.185 | 0 | 0 |
| NTRK2 activates RAC1 | R-HSA-9032759 | 6.679705e-02 | 1.175 | 0 | 0 |
| Loss of phosphorylation of MECP2 at T308 | R-HSA-9022535 | 6.679705e-02 | 1.175 | 0 | 0 |
| Suppression of autophagy | R-HSA-9636569 | 6.679705e-02 | 1.175 | 0 | 0 |
| Reelin signalling pathway | R-HSA-8866376 | 6.679705e-02 | 1.175 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 6.692803e-02 | 1.174 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 6.734065e-02 | 1.172 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 6.804707e-02 | 1.167 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 6.804707e-02 | 1.167 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 6.893453e-02 | 1.162 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 7.240453e-02 | 1.140 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 7.359506e-02 | 1.133 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 7.359506e-02 | 1.133 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 7.359506e-02 | 1.133 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 7.509593e-02 | 1.124 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 7.597035e-02 | 1.119 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 7.597035e-02 | 1.119 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 7.597035e-02 | 1.119 | 0 | 0 |
| Cam-PDE 1 activation | R-HSA-111957 | 7.597035e-02 | 1.119 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 7.597035e-02 | 1.119 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 7.597035e-02 | 1.119 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 7.597035e-02 | 1.119 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 7.642199e-02 | 1.117 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 7.642199e-02 | 1.117 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 7.928294e-02 | 1.101 | 0 | 0 |
| Protein folding | R-HSA-391251 | 8.103376e-02 | 1.091 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 8.217697e-02 | 1.085 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 8.286618e-02 | 1.082 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 8.328295e-02 | 1.079 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 8.471639e-02 | 1.072 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 8.505404e-02 | 1.070 | 0 | 0 |
| VLDL assembly | R-HSA-8866423 | 8.505404e-02 | 1.070 | 0 | 0 |
| NOSTRIN mediated eNOS trafficking | R-HSA-203641 | 9.404898e-02 | 1.027 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 9.404898e-02 | 1.027 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 1.029560e-01 | 0.987 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 1.029560e-01 | 0.987 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 1.205099e-01 | 0.919 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 1.205099e-01 | 0.919 | 0 | 0 |
| Activation of Ca-permeable Kainate Receptor | R-HSA-451308 | 1.205099e-01 | 0.919 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 1.462027e-01 | 0.835 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 1.629155e-01 | 0.788 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 1.711496e-01 | 0.767 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 1.001858e-01 | 0.999 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 1.224129e-01 | 0.912 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 1.256803e-01 | 0.901 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 1.322768e-01 | 0.879 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 1.117761e-01 | 0.952 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 1.362171e-01 | 0.866 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 9.404898e-02 | 1.027 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 1.029560e-01 | 0.987 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 1.205099e-01 | 0.919 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 1.525094e-01 | 0.817 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 1.205099e-01 | 0.919 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 1.462027e-01 | 0.835 | 0 | 0 |
| PTK6 Expression | R-HSA-8849473 | 9.404898e-02 | 1.027 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 1.117761e-01 | 0.952 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 1.629155e-01 | 0.788 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 1.711496e-01 | 0.767 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 1.184448e-01 | 0.926 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 1.117761e-01 | 0.952 | 0 | 0 |
| Ion influx/efflux at host-pathogen interface | R-HSA-6803544 | 1.205099e-01 | 0.919 | 0 | 0 |
| Ionotropic activity of kainate receptors | R-HSA-451306 | 1.291585e-01 | 0.889 | 0 | 0 |
| vRNP Assembly | R-HSA-192905 | 1.291585e-01 | 0.889 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 1.462027e-01 | 0.835 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 1.546002e-01 | 0.811 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 1.546002e-01 | 0.811 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 1.208559e-01 | 0.918 | 1 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 1.117761e-01 | 0.952 | 0 | 0 |
| Chylomicron assembly | R-HSA-8963888 | 1.291585e-01 | 0.889 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 1.711496e-01 | 0.767 | 0 | 0 |
| PI5P Regulates TP53 Acetylation | R-HSA-6811555 | 1.546002e-01 | 0.811 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 1.525094e-01 | 0.817 | 0 | 0 |
| LDL remodeling | R-HSA-8964041 | 9.404898e-02 | 1.027 | 0 | 0 |
| Synthesis of PIPs in the nucleus | R-HSA-8847453 | 9.404898e-02 | 1.027 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 1.029560e-01 | 0.987 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 1.117761e-01 | 0.952 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 1.205099e-01 | 0.919 | 0 | 0 |
| Reduction of cytosolic Ca++ levels | R-HSA-418359 | 1.377224e-01 | 0.861 | 0 | 0 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | R-HSA-442720 | 1.546002e-01 | 0.811 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 1.711496e-01 | 0.767 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 1.001858e-01 | 0.999 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 1.389508e-01 | 0.857 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 1.322768e-01 | 0.879 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 1.497383e-01 | 0.825 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 9.406590e-02 | 1.027 | 0 | 0 |
| Netrin mediated repulsion signals | R-HSA-418886 | 9.404898e-02 | 1.027 | 0 | 0 |
| Sodium/Calcium exchangers | R-HSA-425561 | 1.377224e-01 | 0.861 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 1.711496e-01 | 0.767 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 1.256803e-01 | 0.901 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 1.001858e-01 | 0.999 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 1.001858e-01 | 0.999 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 9.404898e-02 | 1.027 | 0 | 0 |
| Nef Mediated CD4 Down-regulation | R-HSA-167590 | 9.404898e-02 | 1.027 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 1.029560e-01 | 0.987 | 0 | 0 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 1.117761e-01 | 0.952 | 0 | 0 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | R-HSA-428542 | 1.117761e-01 | 0.952 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 1.462027e-01 | 0.835 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 1.462027e-01 | 0.835 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 1.462027e-01 | 0.835 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 1.629155e-01 | 0.788 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 1.711496e-01 | 0.767 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 9.406590e-02 | 1.027 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 1.064135e-01 | 0.973 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 1.629155e-01 | 0.788 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 1.205099e-01 | 0.919 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 1.322768e-01 | 0.879 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 1.122883e-01 | 0.950 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 1.515635e-01 | 0.819 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 1.356045e-01 | 0.868 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 1.462027e-01 | 0.835 | 0 | 0 |
| Other semaphorin interactions | R-HSA-416700 | 1.711496e-01 | 0.767 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 1.201016e-01 | 0.920 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 1.029560e-01 | 0.987 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 1.711496e-01 | 0.767 | 0 | 0 |
| Interleukin-23 signaling | R-HSA-9020933 | 1.029560e-01 | 0.987 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 1.356045e-01 | 0.868 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 8.610599e-02 | 1.065 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 9.588084e-02 | 1.018 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 9.406590e-02 | 1.027 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 9.406590e-02 | 1.027 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 1.407248e-01 | 0.852 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 1.498880e-01 | 0.824 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 1.291585e-01 | 0.889 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 9.104853e-02 | 1.041 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 9.341836e-02 | 1.030 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 1.191670e-01 | 0.924 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 1.322768e-01 | 0.879 | 1 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 9.229171e-02 | 1.035 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 1.732967e-01 | 0.761 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 1.751524e-01 | 0.757 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 1.779223e-01 | 0.750 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 1.779724e-01 | 0.750 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 1.793031e-01 | 0.746 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 1.793031e-01 | 0.746 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 1.793031e-01 | 0.746 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 1.793031e-01 | 0.746 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 1.838574e-01 | 0.736 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 1.838574e-01 | 0.736 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 1.838574e-01 | 0.736 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 1.838574e-01 | 0.736 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 1.873770e-01 | 0.727 | 0 | 0 |
| Fibronectin matrix formation | R-HSA-1566977 | 1.873770e-01 | 0.727 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 1.873770e-01 | 0.727 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 1.873770e-01 | 0.727 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 1.873770e-01 | 0.727 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 1.873770e-01 | 0.727 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 1.873986e-01 | 0.727 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 1.909493e-01 | 0.719 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 1.953719e-01 | 0.709 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 1.953719e-01 | 0.709 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 1.953719e-01 | 0.709 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 1.954216e-01 | 0.709 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 1.980775e-01 | 0.703 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 2.032887e-01 | 0.692 | 0 | 0 |
| PKA activation | R-HSA-163615 | 2.032887e-01 | 0.692 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 2.032887e-01 | 0.692 | 1 | 1 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 2.032887e-01 | 0.692 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 2.088288e-01 | 0.680 | 0 | 0 |
| M Phase | R-HSA-68886 | 2.095945e-01 | 0.679 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 2.111280e-01 | 0.675 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 2.111280e-01 | 0.675 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 2.111280e-01 | 0.675 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 2.111280e-01 | 0.675 | 0 | 0 |
| Strand-asynchronous mitochondrial DNA replication | R-HSA-9913635 | 2.111280e-01 | 0.675 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 2.111280e-01 | 0.675 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 2.124263e-01 | 0.673 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 2.134488e-01 | 0.671 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 2.160299e-01 | 0.665 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 2.160299e-01 | 0.665 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 2.160299e-01 | 0.665 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 2.188907e-01 | 0.660 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 2.232536e-01 | 0.651 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 2.265775e-01 | 0.645 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 2.265775e-01 | 0.645 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 2.265775e-01 | 0.645 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 2.265775e-01 | 0.645 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 2.265775e-01 | 0.645 | 0 | 0 |
| Prevention of phagosomal-lysosomal fusion | R-HSA-9636383 | 2.265775e-01 | 0.645 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 2.288823e-01 | 0.640 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 2.314754e-01 | 0.635 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 2.341891e-01 | 0.630 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 2.341891e-01 | 0.630 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 2.341891e-01 | 0.630 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 2.341891e-01 | 0.630 | 0 | 0 |
| Ribavirin ADME | R-HSA-9755088 | 2.341891e-01 | 0.630 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 2.366779e-01 | 0.626 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 2.377542e-01 | 0.624 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 2.390420e-01 | 0.622 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 2.392870e-01 | 0.621 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 2.410183e-01 | 0.618 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 2.417263e-01 | 0.617 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 2.417263e-01 | 0.617 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 2.450243e-01 | 0.611 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 2.450243e-01 | 0.611 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 2.471433e-01 | 0.607 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 2.486628e-01 | 0.604 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 2.486628e-01 | 0.604 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 2.491897e-01 | 0.603 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 2.491897e-01 | 0.603 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 2.491897e-01 | 0.603 | 0 | 0 |
| Formation of the ureteric bud | R-HSA-9830674 | 2.491897e-01 | 0.603 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 2.491897e-01 | 0.603 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 2.491897e-01 | 0.603 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 2.524035e-01 | 0.598 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 2.559451e-01 | 0.592 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 2.565802e-01 | 0.591 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 2.565802e-01 | 0.591 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 2.565802e-01 | 0.591 | 0 | 0 |
| Mitochondrial RNA degradation | R-HSA-9836573 | 2.565802e-01 | 0.591 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 2.576802e-01 | 0.589 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 2.576802e-01 | 0.589 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 2.638983e-01 | 0.579 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 2.638983e-01 | 0.579 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 2.638983e-01 | 0.579 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 2.638983e-01 | 0.579 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 2.638983e-01 | 0.579 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 2.638983e-01 | 0.579 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 2.638983e-01 | 0.579 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 2.705193e-01 | 0.568 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 2.711449e-01 | 0.567 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 2.711449e-01 | 0.567 | 0 | 0 |
| Suppression of phagosomal maturation | R-HSA-9637687 | 2.711449e-01 | 0.567 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 2.778056e-01 | 0.556 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 2.783206e-01 | 0.555 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 2.783206e-01 | 0.555 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 2.783206e-01 | 0.555 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 2.783206e-01 | 0.555 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 2.814473e-01 | 0.551 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 2.850877e-01 | 0.545 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 2.850877e-01 | 0.545 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 2.854260e-01 | 0.545 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 2.854260e-01 | 0.545 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 2.854260e-01 | 0.545 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 2.854260e-01 | 0.545 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 2.854260e-01 | 0.545 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 2.854260e-01 | 0.545 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 2.854260e-01 | 0.545 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 2.854260e-01 | 0.545 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 2.854260e-01 | 0.545 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 2.854260e-01 | 0.545 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 2.887263e-01 | 0.540 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 2.923629e-01 | 0.534 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 2.923629e-01 | 0.534 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 2.924620e-01 | 0.534 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 2.924620e-01 | 0.534 | 0 | 0 |
| Thyroxine biosynthesis | R-HSA-209968 | 2.924620e-01 | 0.534 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 2.924620e-01 | 0.534 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 2.924620e-01 | 0.534 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 2.924620e-01 | 0.534 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 2.924620e-01 | 0.534 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 2.924620e-01 | 0.534 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 2.959972e-01 | 0.529 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 2.994291e-01 | 0.524 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 2.994291e-01 | 0.524 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 2.994291e-01 | 0.524 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 2.996289e-01 | 0.523 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 3.063280e-01 | 0.514 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 3.063280e-01 | 0.514 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 3.063280e-01 | 0.514 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 3.063280e-01 | 0.514 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 3.063280e-01 | 0.514 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 3.068831e-01 | 0.513 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 3.131594e-01 | 0.504 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 3.131594e-01 | 0.504 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 3.137649e-01 | 0.503 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 3.199239e-01 | 0.495 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 3.199239e-01 | 0.495 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 3.199239e-01 | 0.495 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 3.199239e-01 | 0.495 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 3.199239e-01 | 0.495 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 3.199239e-01 | 0.495 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 3.199239e-01 | 0.495 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 3.199239e-01 | 0.495 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 3.266223e-01 | 0.486 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 3.266223e-01 | 0.486 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 3.266223e-01 | 0.486 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 3.280817e-01 | 0.484 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 3.285526e-01 | 0.483 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 3.321479e-01 | 0.479 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 3.321479e-01 | 0.479 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 3.332550e-01 | 0.477 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 3.332550e-01 | 0.477 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 3.332550e-01 | 0.477 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 3.332550e-01 | 0.477 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 3.332550e-01 | 0.477 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 3.357378e-01 | 0.474 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 3.398229e-01 | 0.469 | 0 | 0 |
| Acyl chain remodelling of PE | R-HSA-1482839 | 3.398229e-01 | 0.469 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 3.398229e-01 | 0.469 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 3.463264e-01 | 0.461 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 3.463264e-01 | 0.461 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 3.463264e-01 | 0.461 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 3.463264e-01 | 0.461 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 3.464729e-01 | 0.460 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 3.486742e-01 | 0.458 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 3.527663e-01 | 0.453 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 3.571515e-01 | 0.447 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 3.654575e-01 | 0.437 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 3.654575e-01 | 0.437 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 3.654575e-01 | 0.437 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 3.654575e-01 | 0.437 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 3.654575e-01 | 0.437 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 3.674818e-01 | 0.435 | 1 | 1 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 3.677678e-01 | 0.434 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 3.677678e-01 | 0.434 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 3.712917e-01 | 0.430 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 3.717101e-01 | 0.430 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 3.717101e-01 | 0.430 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 3.717101e-01 | 0.430 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 3.717101e-01 | 0.430 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 3.717101e-01 | 0.430 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 3.717101e-01 | 0.430 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 3.717101e-01 | 0.430 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 3.717101e-01 | 0.430 | 0 | 0 |
| Infection with Enterobacteria | R-HSA-9640148 | 3.754990e-01 | 0.425 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 3.779014e-01 | 0.423 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 3.779014e-01 | 0.423 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 3.783162e-01 | 0.422 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 3.840321e-01 | 0.416 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 3.840321e-01 | 0.416 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 3.901028e-01 | 0.409 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 3.901028e-01 | 0.409 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 3.961140e-01 | 0.402 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 3.961140e-01 | 0.402 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 4.020656e-01 | 0.396 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 4.079604e-01 | 0.389 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 4.079604e-01 | 0.389 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 4.079604e-01 | 0.389 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 4.079604e-01 | 0.389 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 4.079604e-01 | 0.389 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 4.129253e-01 | 0.384 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 4.137967e-01 | 0.383 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 4.137967e-01 | 0.383 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 4.137967e-01 | 0.383 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 4.195758e-01 | 0.377 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 4.252983e-01 | 0.371 | 0 | 0 |
| Plasma lipoprotein remodeling | R-HSA-8963899 | 4.252983e-01 | 0.371 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 4.265056e-01 | 0.370 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 4.309647e-01 | 0.366 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 4.309647e-01 | 0.366 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 4.365756e-01 | 0.360 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 4.421316e-01 | 0.354 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 4.421316e-01 | 0.354 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 4.421316e-01 | 0.354 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 4.464495e-01 | 0.350 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 4.465662e-01 | 0.350 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 4.476330e-01 | 0.349 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 4.476330e-01 | 0.349 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 4.476330e-01 | 0.349 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 4.476330e-01 | 0.349 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 4.530806e-01 | 0.344 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 4.530806e-01 | 0.344 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 4.530806e-01 | 0.344 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 4.530806e-01 | 0.344 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 4.584748e-01 | 0.339 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 4.629835e-01 | 0.334 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 4.638161e-01 | 0.334 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 4.638161e-01 | 0.334 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 4.691050e-01 | 0.329 | 0 | 0 |
| Metabolism of amine-derived hormones | R-HSA-209776 | 4.691050e-01 | 0.329 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 4.691050e-01 | 0.329 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 4.691050e-01 | 0.329 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 4.694709e-01 | 0.328 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 4.744784e-01 | 0.324 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 4.823056e-01 | 0.317 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 4.846628e-01 | 0.315 | 0 | 0 |
| S Phase | R-HSA-69242 | 4.886516e-01 | 0.311 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 4.897474e-01 | 0.310 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 4.897474e-01 | 0.310 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 4.947821e-01 | 0.306 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 4.949491e-01 | 0.305 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 4.997675e-01 | 0.301 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 4.997675e-01 | 0.301 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 5.047039e-01 | 0.297 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 5.047039e-01 | 0.297 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 5.047039e-01 | 0.297 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 5.073970e-01 | 0.295 | 0 | 0 |
| CD22 mediated BCR regulation | R-HSA-5690714 | 5.095920e-01 | 0.293 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 5.095920e-01 | 0.293 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 5.104779e-01 | 0.292 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 5.166021e-01 | 0.287 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 5.239704e-01 | 0.281 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 5.239704e-01 | 0.281 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 5.286694e-01 | 0.277 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 5.286694e-01 | 0.277 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 5.376364e-01 | 0.270 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 5.379298e-01 | 0.269 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 5.379298e-01 | 0.269 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 5.379298e-01 | 0.269 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 5.424919e-01 | 0.266 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 5.426888e-01 | 0.265 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 5.470093e-01 | 0.262 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 5.470093e-01 | 0.262 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 5.514823e-01 | 0.258 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 5.514823e-01 | 0.258 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 5.559115e-01 | 0.255 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 5.559115e-01 | 0.255 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 5.602971e-01 | 0.252 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 5.609000e-01 | 0.251 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 5.646398e-01 | 0.248 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 5.668559e-01 | 0.247 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 5.731976e-01 | 0.242 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 5.833230e-01 | 0.234 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 5.942167e-01 | 0.226 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 5.978809e-01 | 0.223 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 6.018546e-01 | 0.221 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 6.018546e-01 | 0.221 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 6.057893e-01 | 0.218 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 6.057893e-01 | 0.218 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 6.057893e-01 | 0.218 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 6.096853e-01 | 0.215 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 6.096853e-01 | 0.215 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 6.098417e-01 | 0.215 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 6.135430e-01 | 0.212 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 6.173629e-01 | 0.209 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 6.285988e-01 | 0.202 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 6.285988e-01 | 0.202 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 6.322707e-01 | 0.199 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 6.359066e-01 | 0.197 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 6.359066e-01 | 0.197 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 6.381476e-01 | 0.195 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 6.430715e-01 | 0.192 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 6.430715e-01 | 0.192 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 6.455040e-01 | 0.190 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 6.466012e-01 | 0.189 | 0 | 0 |
| Mitochondrial Fatty Acid Beta-Oxidation | R-HSA-77289 | 6.466012e-01 | 0.189 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 6.500963e-01 | 0.187 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 6.605948e-01 | 0.180 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 6.637363e-01 | 0.178 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 6.703569e-01 | 0.174 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 6.736184e-01 | 0.172 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 6.736184e-01 | 0.172 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 6.736184e-01 | 0.172 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 6.768479e-01 | 0.170 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 6.782861e-01 | 0.169 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 6.800456e-01 | 0.167 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 6.800456e-01 | 0.167 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 6.805313e-01 | 0.167 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 6.832118e-01 | 0.165 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 6.863470e-01 | 0.163 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 6.894513e-01 | 0.161 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 6.925250e-01 | 0.160 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 6.925250e-01 | 0.160 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 6.925250e-01 | 0.160 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 6.925250e-01 | 0.160 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 6.941050e-01 | 0.159 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 6.955685e-01 | 0.158 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 6.985821e-01 | 0.156 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 7.045206e-01 | 0.152 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 7.074462e-01 | 0.150 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 7.074462e-01 | 0.150 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 7.074462e-01 | 0.150 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 7.208129e-01 | 0.142 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 7.216475e-01 | 0.142 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 7.271344e-01 | 0.138 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 7.377876e-01 | 0.132 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 7.377876e-01 | 0.132 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 7.429582e-01 | 0.129 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 7.567582e-01 | 0.121 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 7.650000e-01 | 0.116 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 7.696371e-01 | 0.114 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 7.696371e-01 | 0.114 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 7.696371e-01 | 0.114 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 7.808360e-01 | 0.107 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 7.851625e-01 | 0.105 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 7.851625e-01 | 0.105 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 7.996477e-01 | 0.097 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 8.055546e-01 | 0.094 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 8.055546e-01 | 0.094 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 8.150172e-01 | 0.089 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 8.186728e-01 | 0.087 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 8.196102e-01 | 0.086 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 8.257701e-01 | 0.083 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 8.359016e-01 | 0.078 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 8.500114e-01 | 0.071 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 8.515027e-01 | 0.070 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 8.544413e-01 | 0.068 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 8.587412e-01 | 0.066 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 8.641635e-01 | 0.063 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 8.820148e-01 | 0.055 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 8.888920e-01 | 0.051 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 8.899988e-01 | 0.051 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 8.947611e-01 | 0.048 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 9.062887e-01 | 0.043 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 9.135106e-01 | 0.039 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 9.201791e-01 | 0.036 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.262982e-01 | 0.033 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 9.313356e-01 | 0.031 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 9.320217e-01 | 0.031 | 0 | 0 |
| Translation | R-HSA-72766 | 9.385149e-01 | 0.028 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 9.486967e-01 | 0.023 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 9.673970e-01 | 0.014 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 9.723204e-01 | 0.012 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 9.740848e-01 | 0.011 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 9.775637e-01 | 0.010 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 9.824019e-01 | 0.008 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 9.847293e-01 | 0.007 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 9.862019e-01 | 0.006 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 9.862377e-01 | 0.006 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 9.866072e-01 | 0.006 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 9.878913e-01 | 0.005 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 9.881502e-01 | 0.005 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 9.930184e-01 | 0.003 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 9.957645e-01 | 0.002 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 9.997471e-01 | 0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 9.998590e-01 | 0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 9.999129e-01 | 0.000 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 1.000000e+00 | 0.000 | 1 | 1 |